<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-0420</journal-id>
<journal-title><![CDATA[Revista Uruguaya de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev.Urug.Cardiol.]]></abbrev-journal-title>
<issn>1688-0420</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Uruguaya de Cardiología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-04202011000200009</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Valor del electrocardiograma en el diagnóstico y pronóstico del síndrome de Brugada]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[PÉREZ-RIERA]]></surname>
<given-names><![CDATA[ANDRÉS RICARDO]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[FEMENíA]]></surname>
<given-names><![CDATA[FRANCISCO]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[BARANCHUK FACC]]></surname>
<given-names><![CDATA[ADRIÁN]]></given-names>
</name>
<xref ref-type="aff" rid="A03"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Fundação do ABC Faculdade de Medicina do ABC ]]></institution>
<addr-line><![CDATA[Santo André São Paulo]]></addr-line>
<country>Brasil</country>
</aff>
<aff id="A02">
<institution><![CDATA[,Hospital Español de Mendoza Departamento de Cardiología Unidad de Arritmias]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Argentina</country>
</aff>
<aff id="A03">
<institution><![CDATA[,Queen's University Heart Rhythm Service ]]></institution>
<addr-line><![CDATA[ São Paulo]]></addr-line>
<country>Brasil</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2011</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2011</year>
</pub-date>
<volume>26</volume>
<numero>2</numero>
<fpage>122</fpage>
<lpage>140</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-04202011000200009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-04202011000200009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-04202011000200009&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[El electrocardiograma de 12 derivaciones asociado con las derivadas accesorias (precordiales derechas altas) es el método complementario con el cual se obtiene la mayor información diagnóstica y pronostica en pacientes portadores con síndrome de Brugada. Mediante este método sencillo, económico, reproducible y operador independiente, podemos estudiar las alteraciones tanto de la despolarización como de la repolarización ventricular. También permite el diagnóstico de las distintas arritmias supraventriculares que pueden acontecer así como caracterizar las diferentes taquicardias ventriculares. Por otro lado, el análisis vectocardiográfico con el método de Frank en pacientes con síndrome de Brugada, sugiere la dualidad de los mecanismos fisiopatológicos del patrón electrocardiográfico característico o tipo 1, demostrándose características distintivas y particulares, con respecto a individuos portadores de bloqueo de rama derecha. La compresión de todos estos mecanismos, pueden contribuir a orientar futuros esfuerzos terapéuticos que permitan controlar la disfunción de los canales asociados a esta rara y compleja canalopatía.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Twelve-lead ECG associated to high right parasternal accessory leads is the resource that yields a greatest number of diagnostic and prognostic information in patients carriers of BrS. By this simple, cheap, reproducible, and operator-independent method, depolarization alterations can be studied as well as ventricular repolarization aspects. The method allows diagnosing frequent episodes of atrial fibrillation and other supraventricular arrhythmias, as well as characterizing the different ventricular tachyarrhythmias. The analysis of the Frank VCG (F-VCG) of patients with BrS suggests the duality of the underlying physiopathological mechanisms of the Brugada Type-1 ECG pattern. F-VCG of patients with Brugada type-1 ECG pattern has distinctive characteristics from the F-VCG of individuals with RBBB pattern. The understanding of these mechanisms may help to guide future therapeutic efforts to control the channels dysfunction associated with this intriguing channelopaty.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[ELECTROCARDIOGRAMA]]></kwd>
<kwd lng="es"><![CDATA[SíNDROME DE BRUGADA- diagnóstico]]></kwd>
<kwd lng="es"><![CDATA[SíNDROME DE BRUGADA- pronóstico]]></kwd>
<kwd lng="en"><![CDATA[ELECTROCARDIOGRAM]]></kwd>
<kwd lng="en"><![CDATA[BRUGADA SYNDROME- diagnosis]]></kwd>
<kwd lng="en"><![CDATA[BRUGADA SYNDROME- prognosis]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[       <basefont size="3"> <multicol gutter="18" cols="2"></multicol>     <p align="left"><font color="#1f1a17" face="Verdana" size="2">ART&Iacute;CULO DE REVISI&Oacute;N&nbsp; </font> <font face="Verdana" size="2">    <br>        &nbsp;</font></p>          <p align="left">&nbsp;</p>          <p align="left"><b> <font color="#1f1a17" face="Verdana" size="4">Valor del electrocardiograma en el diagn&oacute;stico      y pron&oacute;stico del s&iacute;ndrome  de Brugada&nbsp; </font></b></p>      <font face="Verdana" size="2">          <br>      </font>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> DRES. ANDR&Eacute;S RICARDO P&Eacute;REZ-RIERA PHD </font><font color="#1f1a17" face="Swis721 LtCn BT" size="2"> <a href="#a1"><font color="#1f1a17" face="Verdana"><sup>1</sup></font></a><font color="#1f1a17" face="Verdana" size="2">, FRANCISCO FEMEN&iacute;A </font><a href="#a2"> <font color="#1f1a17" face="Verdana"><sup>2</sup></font></a><font color="#1f1a17" face="Verdana" size="2">, ADRI&Aacute;N BARANCHUK  FACC </font><a href="#a3"><font color="#1f1a17" face="Verdana"><sup>3</sup></font></a><font color="#1f1a17" face="Verdana" size="2">&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>      <basefont size="3">     <p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="a1"></a> 1. Faculdade de Medicina do ABC Funda&ccedil;&atilde;o do ABC. Santo Andr&eacute;, S&atilde;o Paulo,   Brasil.    <br>     <a name="a2"></a>   2. Unidad de Arritmias, Departamento de Cardiolog&iacute;a, Hospital Espa&ntilde;ol   de Mendoza, Argentina.    <br>     <a name="a3"></a>   3. Heart Rhythm Service, Queen&rsquo;s University, Kingston,   Ontario, Canada.    ]]></body>
<body><![CDATA[<br>         <b>Correspondencia</b>: Andr&eacute;s Ricardo P&eacute;rez-Riera MD. Rua Sebasti&atilde;o   Afonso, 885. CEP: 04417-000 Jardim Miriam. S&atilde;o Paulo, Brasil. Correo electr&oacute;nico:   <a href="riera@uol.com.br">riera@uol.com.br</a>    <br>        Los autores no refieren ning&uacute;n conflicto de inter&eacute;s    <br>        Recibido   julio 11, 2011; aceptado julio 26, 2011.&nbsp; </font></p>      <font face="Verdana" size="2">          <br>      </font>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> <b>RESUMEN&nbsp;</b> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> El electrocardiograma de 12 derivaciones asociado con las derivadas accesorias  (precordiales derechas altas) es el m&eacute;todo complementario con el cual se  obtiene la mayor informaci&oacute;n diagn&oacute;stica y pronostica en pacientes portadores  con s&iacute;ndrome de Brugada.    <br>      Mediante este m&eacute;todo sencillo, econ&oacute;mico, reproducible  y operador independiente, podemos estudiar las alteraciones tanto de la  despolarizaci&oacute;n como de la repolarizaci&oacute;n ventricular. Tambi&eacute;n permite  el diagn&oacute;stico de las distintas arritmias supraventriculares que pueden  acontecer as&iacute; como caracterizar las diferentes taquicardias ventriculares.    <br>      Por  otro lado, el an&aacute;lisis vectocardiogr&aacute;fico con el m&eacute;todo de Frank en pacientes  con s&iacute;ndrome de Brugada, sugiere la dualidad de los mecanismos fisiopatol&oacute;gicos  del patr&oacute;n electrocardiogr&aacute;fico caracter&iacute;stico o tipo 1, demostr&aacute;ndose  caracter&iacute;sticas distintivas y particulares, con respecto a individuos portadores  de bloqueo de rama derecha.    <br>      La compresi&oacute;n de todos estos mecanismos, pueden  contribuir a orientar futuros esfuerzos terap&eacute;uticos que permitan controlar  la disfunci&oacute;n de los canales asociados a esta rara y compleja canalopat&iacute;a.      <br>      &nbsp; </font></p>          ]]></body>
<body><![CDATA[<p align="left"><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana">PALABRAS CLAVE</font><font color="#1f1a17" face="Verdana" size="2">:    <br>      &nbsp;&nbsp;&nbsp;&nbsp;ELECTROCARDIOGRAMA     <br>      &nbsp;&nbsp;&nbsp;&nbsp;S&iacute;NDROME DE BRUGADA-diagn&oacute;stico    <br>      &nbsp;&nbsp;&nbsp;&nbsp;S&iacute;NDROME  DE BRUGADA-pron&oacute;stico&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>     <font face="Verdana" size="2">         <br>      </font>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> <b>SUMMARY&nbsp;</b> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Twelve-lead ECG associated to high right parasternal accessory leads is  the resource that yields a greatest number of diagnostic and prognostic  information in patients carriers of BrS.    <br>      By this simple, cheap, reproducible,  and operator-independent method, depolarization alterations can be studied  as well as ventricular repolarization aspects.    <br>      The method allows diagnosing  frequent episodes of atrial fibrillation and other supraventricular arrhythmias,  as well as characterizing the different ventricular tachyarrhythmias.    <br>      The  analysis of the Frank VCG (F-VCG) of patients with BrS suggests the duality  of the underlying physiopathological mechanisms of the Brugada Type-1 ECG  pattern. F-VCG of patients with Brugada type-1 ECG pattern has distinctive  characteristics from the F-VCG of individuals with RBBB pattern. The understanding  of these mechanisms may help to guide future therapeutic efforts to control  the channels dysfunction associated with this intriguing channelopaty.&nbsp; </font></p>          ]]></body>
<body><![CDATA[<p align="left"><font color="#1f1a17" face="Verdana" size="2">KEY WORDS:    <br>          &nbsp;&nbsp;&nbsp;&nbsp;ELECTROCARDIOGRAM     <br>      &nbsp;&nbsp;&nbsp;&nbsp;BRUGADA SYNDROME-diagnosis    <br>      &nbsp;&nbsp;&nbsp;&nbsp;BRUGADA SYNDROME-prognosis&nbsp;</font></p>      <font face="Verdana" size="2">          <br>       </font>       <multicol gutter="18" cols="2"></multicol>     <p align="left"><font color="#1f1a17" face="Verdana" size="2"> <b>INTRODUCCI&oacute;N&nbsp;</b> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> El s&iacute;ndrome de Brugada (SBr) es una canalopat&iacute;a cl&iacute;nico-electrocardiogr&aacute;fica  hereditaria, familiar, autos&oacute;mica dominante polig&eacute;nica de incompleta y  baja penetrancia o espor&aacute;dica, que afecta predominantemente el epicardio  del tracto de salida del ventr&iacute;culo derecho (TSVD) </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b1"><font color="#1f1a17" face="Verdana"><sup>1</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2">.<a name=".1"></a>&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Cl&iacute;nicamente se manifiesta por s&iacute;ncope o muerte s&uacute;bita card&iacute;aca que ocurre  durante el reposo o el sue&ntilde;o nocturno (85% de los casos), consecuencia  de episodios de taquicardia ventricular polim&oacute;rfica (TVP) que pueden degenerar  en fibrilaci&oacute;n ventricular (FV) en ausencia de cardiopat&iacute;a estructural  aparente, efecto de f&aacute;rmacos, insuficiencia coronaria, o desequilibrio  electrol&iacute;tico </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(<a href="#b2">2</a>,</sup></font><a href="#b3"><font color="#1f1a17" face="Verdana"><sup>3</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2">.<a name=".2"></a><a name=".3"></a>&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Desde el punto de vista electrocardiogr&aacute;fico el diagn&oacute;stico solo es posible  con el registro, espont&aacute;neo o desenmascarado con f&aacute;rmacos espec&iacute;ficos,  del denominado patr&oacute;n electrocardiogr&aacute;fico tipo 1 o signo de Brugada,</font><font color="#1f1a17" face="Century Schoolbook" size="2"><font color="#1f1a17" face="Verdana"><sup> </sup></font> <font color="#1f1a17" face="Verdana" size="2">consistente  en elevaci&oacute;n del punto J y segmento ST &sup3; 2 mm de convexidad superior seguido  de onda T negativa en derivaciones precordiales derechas (V</font><font color="#1f1a17" face="Verdana"><sub>1</sub></font><font color="#1f1a17" face="Verdana" size="2">-V</font><font color="#1f1a17" face="Verdana"><sub>2</sub></font><font color="#1f1a17" face="Verdana" size="2"> o de V</font><font color="#1f1a17" face="Verdana"><sub>1</sub></font><font color="#1f1a17" face="Verdana" size="2">  a V</font><font color="#1f1a17" face="Verdana"><sub>3</sub></font><font color="#1f1a17" face="Verdana" size="2">) y/o precordiales derechas altas (V</font><font color="#1f1a17" face="Verdana"><sub>1H</sub></font><font color="#1f1a17" face="Verdana" size="2">, V</font><font color="#1f1a17" face="Verdana"><sub>2H</sub></font><font color="#1f1a17" face="Verdana" size="2"> y V</font><font color="#1f1a17" face="Verdana"><sub>3H</sub></font><font color="#1f1a17" face="Verdana" size="2">) </font> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b4"><font color="#1f1a17" face="Verdana"><sup>4</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".4"></a> (<a href="#Figur1">figura 1</a>).&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>            <p><font face="Verdana" size="2"><a name="Figur1"></a><img style="width: 566px; height: 233px;" alt="" src="/img/revistas/ruc/v26n2/2a09f1.JPG">    ]]></body>
<body><![CDATA[<br>    </font>    <small><small><small><font face="Verdana" size="2"><span style="font-weight: bold;">FIGURA 1</span>. Se observa el caracter&iacute;stico patr&oacute;n electrocardiogr&aacute;fico tipo 1 o signo de Brugada caracterizado por la elevaci&oacute;n del punto J y segmento&nbsp;    <br>    ST </font> <font color="#1f1a17" face="Century Schoolbook" size="2"><small><small><small> <font color="#1f1a17" face="Verdana" size="2">&sup3;</font></small></small></small></font><font face="Verdana" size="2"> 2 mm  de convexidad superior seguido de onda T negativa en las precordiales derechas y  derechas altas (V1H, V2H y V3H).</font></small></small></small></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Como observaci&oacute;n es importante destacar que la derivaci&oacute;n V</font><font color="#1f1a17" face="Century Schoolbook" size="2"><font color="#1f1a17" face="Verdana"><sub>3</sub></font><font color="#1f1a17" face="Verdana" size="2"> raramente  presenta el patr&oacute;n tipo 1 y nunca lo muestra en forma aislada, es decir  sin que aparezca en V</font><font color="#1f1a17" face="Verdana"><sub>1</sub></font><font color="#1f1a17" face="Verdana" size="2">-V</font><font color="#1f1a17" face="Verdana"><sub>2</sub></font><font color="#1f1a17" face="Verdana" size="2"> </font> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b4"><font color="#1f1a17" face="Verdana"><sup>4</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2">.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> La simple presencia del patr&oacute;n tipo 1 en ausencia de s&iacute;ntomas no debe ser  considerado s&iacute;ndrome, pero amerita el estudio del paciente en profundidad  para determinar si se trata de un paciente asintom&aacute;tico portador de la  enfermedad o de una fenocopia, es decir, de aquel paciente que tiene otra  causa capaz de generar el patr&oacute;n electrocardiogr&aacute;fico tipo 1 (formas adquiridas  o fenocopias).&nbsp; </font></p>     <font face="Verdana" size="2">         <br>      </font>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> <b>PRINCIPALES ELEMENTOS EPIDEMIOL&oacute;GICOS&nbsp;</b> </font></p>      <ul>            <li><font color="#1f1a17" face="Verdana" size="2">     <i>Edad: </i>se observa m&aacute;s frecuentemente en individuos adultos j&oacute;venes (edad  promedio del primer evento 40 a&ntilde;os).&nbsp;     </font></li>            <li><font color="#1f1a17" face="Verdana" size="2">     <i>Raza:</i> prevalencia mayor en la etnia asi&aacute;tica-amarilla (&raquo; 60% de todos los  casos).&nbsp;     </font></li>            <li><font color="#1f1a17" face="Verdana" size="2">     <i>Sexo:</i> gran predominio del g&eacute;nero masculino (8:1).&nbsp;     </font></li>          </ul>          ]]></body>
<body><![CDATA[<p align="left"><font color="#1f1a17" face="Verdana" size="2"> La presente revisi&oacute;n tiene como objetivo mostrar las caracter&iacute;sticas electrocardiogr&aacute;ficas  diagn&oacute;sticas del s&iacute;ndrome y estratificar el valor pron&oacute;stico de algunos  hallazgos electrocardiogr&aacute;ficos.&nbsp; </font></p>     <font face="Verdana" size="2">         <br>      </font>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> <b>CARACTERIZACI&oacute;N ELECTROCARDIOGR&aacute;FICA&nbsp;</b> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Estudiaremos sucesivamente las caracter&iacute;sticas del ritmo, frecuencia card&iacute;aca,  onda P, intervalo PR o PQ, eje el&eacute;ctrico del QRS en el plano frontal (S&Acirc;QRS),  duraci&oacute;n del intervalo QRS, los patrones morfol&oacute;gicos del complejo QRS,  incluyendo las alteraciones de conducci&oacute;n en el sistema hisiano derecho,  eventual presencia de extremo desv&iacute;o del eje del QRS para la izquierda  que puede significar bloqueo fascicular anterior izquierdo o bloqueo fascicular  superior de la rama derecha, la eventual presencia de fragmentaci&oacute;n del  QRS (fQRS) y del &ldquo;signo de aVR&rdquo;, los aspectos vinculados con la repolarizaci&oacute;n  ventricular (elevaci&oacute;n del punto J, segmento ST, alternancia de la onda  T y la excepcional aparici&oacute;n de onda &eacute;psilon), la duraci&oacute;n del intervalo  QT/QTc, del intervalo transcurrido desde el &aacute;pice hasta el fin de la onda  T (&ldquo;T</font><font color="#1f1a17" face="Century Schoolbook" size="2"><font color="#1f1a17" face="Verdana"><sub>peak</sub></font><font color="#1f1a17" face="Verdana" size="2">-T</font><font color="#1f1a17" face="Verdana"><sub>end</sub></font><font color="#1f1a17" face="Verdana" size="2"> interval o Tpe&rdquo;), as&iacute; como la relaci&oacute;n del intervalo &aacute;pice  de T-T-fin/QT (&ldquo;T</font><font color="#1f1a17" face="Verdana"><sub>peak</sub></font><font color="#1f1a17" face="Verdana" size="2">-T</font><font color="#1f1a17" face="Verdana"><sub>end</sub></font><font color="#1f1a17" face="Verdana" size="2">/QT ratio&rdquo;. Analizaremos tambi&eacute;n las arritmias  supraventriculares y ventriculares.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Finalmente abordaremos el denominado fenotipo Brugada at&iacute;pico, variante  del SBr, fibrilaci&oacute;n ventricular idiop&aacute;tica asociada al patr&oacute;n de repolarizaci&oacute;n  precoz o s&iacute;ndrome de Ha&iuml;ssaguerre.&nbsp; </font></p>     <font face="Verdana" size="2">         <br>      </font>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> <b>RITMO&nbsp;</b> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> El ritmo sinusal est&aacute; presente en aproximadamente 80% de los casos, no  obstante se observa una cierta tendencia a la p&eacute;rdida del mismo ya que  las alteraciones electrofisiol&oacute;gicas condicionadas por las mutaciones gen&eacute;ticas  afectan tanto al n&oacute;dulo sinusal como al tejido auricular.&nbsp; </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Un estudio realizado en dos familias por Smits y colaboradores </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b5"><font color="#1f1a17" face="Verdana"><sup>5</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".5"></a>, ha  identificado la mutaci&oacute;n E161K en el canal de sodio, la cual se manifest&oacute;  fenot&iacute;picamente con el SBr, la enfermedad progresiva de la conducci&oacute;n,  y disfunci&oacute;n del n&oacute;dulo sinusal.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Sumiyoshi y colaboradores </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b6"><font color="#1f1a17" face="Verdana"><sup>6</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".6"></a> estudiaron cinco pacientes sintom&aacute;ticos,  de los cuales tres ten&iacute;an pausas sinusales documentadas mayores a 3 segundos.  El estudio electrofisiol&oacute;gico de esta peque&ntilde;a serie revel&oacute; un tiempo de  recuperaci&oacute;n del n&oacute;dulo sinusal prolongado en dos.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>       <multicol gutter="18" cols="2"></multicol>     ]]></body>
<body><![CDATA[<p align="left"><font color="#1f1a17" face="Verdana" size="2"> Mutaciones en el gen SCN5A, que codifica el canal de sodio [Na (v) 1.5]  pueden causar una gama amplia de s&iacute;ndromes arr&iacute;tmicos con o sin cardiopat&iacute;a  estructural como el s&iacute;ndrome de QT prolongado variante 3, SBr/s&iacute;ndrome  de la muerte inesperada nocturna, fibrilaci&oacute;n ventricular idiop&aacute;tica, s&iacute;ndrome  de la muerte s&uacute;bita infantil, enfermedad de Len&eacute;gre o enfermedad progresiva  del sistema de conducci&oacute;n, disfunci&oacute;n del n&oacute;dulo sinusal, fibrilaci&oacute;n auricular,  paro auricular, miocardiopat&iacute;a dilatada as&iacute; como entidades mixtas o s&iacute;ndromes  superpuestos </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(<a href="#b7">7</a>-<a href="#b9">9</a>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".7"></a><a name=".8"></a><a name=".9"></a>.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Neu y colaboradores </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b10"><font color="#1f1a17" face="Verdana"><sup>10</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)<a name=".10"></a> </sup></font> <font color="#1f1a17" face="Verdana" size="2">identificaron una rara condici&oacute;n cl&iacute;nica asociada  a una nueva mutaci&oacute;n en el gen SCN5A (p.I230T), responsable de la p&eacute;rdida  de la funci&oacute;n del canal de sodio y un nuevo tipo de fenotipo caracterizado  por disfunci&oacute;n del n&oacute;dulo sinusal, enfermedad del sistema conducci&oacute;n intraventricular  progresiva y arritmias complejas. A diferencia de la mayor&iacute;a de las canalopat&iacute;as  que afectan el canal de sodio informadas hasta el presente momento, esta  mutaci&oacute;n muestra un s&iacute;ndrome de herencia recesiva que no parece seguir  las reglas mendelianas.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>     <font face="Verdana" size="2">         <br>      </font>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> <b>FRECUENCIA CARD&iacute;ACA&nbsp;</b> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Como se describi&oacute; anteriormente, puede existir bradicardia sintom&aacute;tica  secundaria a disfunci&oacute;n del n&oacute;dulo sinusal. La prevalencia del patr&oacute;n Brugada  tipo 1 en pacientes con s&iacute;ndrome del n&oacute;dulo sinusal enfermo, parece ser  mayor que el de la poblaci&oacute;n general. Este subgrupo de pacientes con SBr  y con compromiso del nodo sinusal tiene un mayor riesgo para el desarrollo  de FV espont&aacute;nea </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(<a href="#b11">11</a>,</sup></font><a href="#b12"><font color="#1f1a17" face="Verdana"><sup>12</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2">.<a name=".11"></a><a name=".12"></a>&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>     <font face="Verdana" size="2">         <br>      </font>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> <b>ONDA P&nbsp;</b> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> La eventual observaci&oacute;n de prolongaci&oacute;n en la duraci&oacute;n de la onda P as&iacute;  como del intervalo PR y del intervalo QRS en el electrocardiograma (ECG)  de superficie tienen por mecanismo subyacente la alteraci&oacute;n de despolarizaci&oacute;n.  Del mismo modo, la prolongaci&oacute;n en el electrograma hisiano de los intervalos  AH (aur&iacute;cula-His) y HV (His-ventr&iacute;culo) responden a este mecanismo y se  encuentran significativamente prolongados en los pacientes con SBr que  desarrollan arritmias supraventriculares </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b13"><font color="#1f1a17" face="Verdana"><sup>13</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2">.<a name=".13"></a>&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Una discreta prolongaci&oacute;n en la duraci&oacute;n de la onda P es encontrada con  frecuencia en los portadores de la mutaci&oacute;n en el gen SCN5A. En este grupo  de pacientes, el test provocativo con flecainida ocasiona mayor prolongaci&oacute;n  en la duraci&oacute;n de la onda P </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b14"><font color="#1f1a17" face="Verdana"><sup>14</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".14"></a>.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> La <a href="#Figur2">figura 2</a> muestra el registro electrocardiogr&aacute;fico de la onda P realizado  antes e inmediatamente despu&eacute;s del test farmacol&oacute;gico con ajmalina (1 mg/kg)  en un caso de SBr sintom&aacute;tico en el cual el estudio gen&eacute;tico para el gen  SCN5A fue positivo.&nbsp; </font></p>            ]]></body>
<body><![CDATA[<p><font face="Verdana"><a name="Figur2"><font size="2"></font></a> <font size="2"><img style="width: 566px; height: 188px;" alt="" src="/img/revistas/ruc/v26n2/2a09f2.JPG">    <br>    </font>    <small><small><span style="font-weight: bold;"><font size="2">Figura 2</font></span><font size="2">. Registro electrocardiogr&aacute;fico de la onda P en un paciente con SBr realizado antes e inmediatamente despu&eacute;s del test farmacol&oacute;gico con ajmalina (1 mg/kg). La duraci&oacute;n de la onda P antes de la inyecci&oacute;n est&aacute; prolongada [duraci&oacute;n de P (Pd) = 135 ms], luego de la administraci&oacute;n del f&aacute;rmaco aumenta su duraci&oacute;n (Pd =162 ms).</font></small></small></font></p>           <p align="left"><font color="#1f1a17" face="Verdana" size="2"> El retraso de la conducci&oacute;n intraauricular y su heterogeneidad se ha comprobado  en los pacientes con SBr, especialmente en aquellos con el patr&oacute;n tipo  1 espont&aacute;neo. Estos disturbios dromotropos auriculares son el sustrato  electrofisiol&oacute;gico de las taquiarritmias auriculares como la fibrilaci&oacute;n  auricular (FA). Este retraso ha sido confirmado recientemente empleando  ECG de se&ntilde;ales promediadas auriculares </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(<a href="#b13">13</a>,<a href="#b15">15</a>)</sup></font><font color="#1f1a17" face="Verdana" size="2">.<a name=".15"></a>&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>       <multicol gutter="18" cols="2"></multicol>     <p align="left"><font color="#1f1a17" face="Verdana" size="2"> <b>INTERVALO PR&nbsp;</b> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> El bloqueo auriculoventricular (AV) de primer grado se observa en alrededor  de 50% de los casos de SBr, especialmente cuando es identificada la mutaci&oacute;n  en el gen SCN5A.&nbsp; </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Smits y colaboradores </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b15"><font color="#1f1a17" face="Verdana"><sup>15</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2"> observaron que pacientes con SBr en quienes  se demuestra la mutaci&oacute;n (~20% de los casos), presentan un intervalo PR  m&aacute;s prolongado que aquellos pacientes portadores del s&iacute;ndrome pero sin  la mutaci&oacute;n. Un intervalo PR de 210 ms en el ECG de superficie asociado  a un intervalo HV &sup3; 60 ms en el electrograma hisiano, son predictores de  la presencia de la mutaci&oacute;n SCN5A. Adem&aacute;s, despu&eacute;s de la inyecci&oacute;n de bloqueadores  del canal de sodio, los portadores de la mutaci&oacute;n muestran intervalos PR  y QRS de mayor duraci&oacute;n. La <a href="#Figur3">figura 3</a> revela el caso de un paciente con  SBr sintom&aacute;tico, realizado inmediatamente despu&eacute;s del test farmacol&oacute;gico  con ajmalina (1 mg/kg).&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>           <p><font face="Verdana"><a name="Figur3"><font size="2"></font></a> <font size="2"><img style="width: 274px; height: 140px;" alt="" src="/img/revistas/ruc/v26n2/2a09f3.JPG">    <br>     </font>     <small><small><span style="font-weight: bold;"><font size="2">Figura 3.</font></span><font size="2"> Se muestra la derivaci&oacute;n V2 de un paciente con SBr sintom&aacute;tico posterior al test farmacol&oacute;gico con ajmalina (1 mg/kg).&nbsp;    <br>     Se observa el intervalo PR prolongado (250 ms), con bloqueo AV de primer grado asociado al patr&oacute;n tipo 1 de Brugada.&nbsp;    <br>     El test farmacol&oacute;gico de provocaci&oacute;n fue considerado positivo.</font></small></small></font></p>           ]]></body>
<body><![CDATA[<p align="left"><font color="#1f1a17" face="Verdana" size="2"> Aquellos pacientes con el patr&oacute;n tipo 1 espont&aacute;neo asociado a un intervalo  PR </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana" size="2">&sup3; 170 ms y/o a una onda T negativa de mayor profundidad en la derivaci&oacute;n  V</font><font color="#1f1a17" face="Verdana"><sub>1</sub></font><font color="#1f1a17" face="Verdana" size="2"> presentaron peor pron&oacute;stico durante el seguimiento </font> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b16"><font color="#1f1a17" face="Verdana"><sup>16</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2">.<a name=".16"></a>&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>     <font face="Verdana" size="2">         <br>      </font>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> <b>EJE EL&eacute;CTRICO DEL QRS EN EL PLANO FRONTAL (S&Acirc;QRS)&nbsp;</b> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> El S&Acirc;QRS es normal en la mayor&iacute;a de los casos (90%), pero en cerca de 10%  se verifica extremo desv&iacute;o hacia la izquierda, lo que sugiere una posible  asociaci&oacute;n con bloqueo fascicular anterior izquierdo (BFAI)</font><font color="#1f1a17" face="Century Schoolbook" size="2"><font color="#1f1a17" face="Verdana"><sup> (</sup></font><a href="#b17"><font color="#1f1a17" face="Verdana"><sup>17</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".17"></a> (<a href="#Figur4">figura  4</a>). No obstante, un an&aacute;lisis detallado de la morfolog&iacute;a del QRS en este  plano y las caracter&iacute;sticas del bucle del QRS del vectocardiograma puede  revelarnos ocasionalmente que se trata de un bloqueo fascicular superior  de la rama derecha (BFSRD) y no de un BFAI </font> <font color="#1f1a17" face="Verdana"><sup>(<a href="#b18">18</a>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".18"></a>. <a href="#Figur5">La figura 5</a> muestra los  criterios electro-vectocardiogr&aacute;ficos (ECG/VCG) que diferencian ambos disturbios  dromotropos.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>           <p><font face="Verdana"><a name="Figur4"><font size="2"></font></a> <font size="2"><img style="width: 566px; height: 353px;" alt="" src="/img/revistas/ruc/v26n2/2a09f4.JPG">    <br>     </font>     <small><small><span style="font-weight: bold;"><font size="2">Figura 4</font></span><font size="2">. ECG de un paciente con SBr sintom&aacute;tico, observ&aacute;ndose el patr&oacute;n electrocardiogr&aacute;fico tipo 1 con desviaci&oacute;n del eje el&eacute;ctrico del QRS hacia    <br>     la izquierda (eje el&eacute;ctrico en el plano frontal pr&oacute;ximo a -80&ordm;). Un an&aacute;lisis superficial puede hacernos pensar en la presencia de bloqueo de la rama antero&nbsp;    <br>     superior izquierda. Otro hallazgo en este ECG es la presencia de onda R final en aVR, con un voltaje &gt; 3 mm (signo de aVR).&nbsp;    <br>     Cuando est&aacute; presente, se relaciona con una mayor incidencia de eventos arr&iacute;tmicos graves.</font></small></small></font></p>          <p><font face="Verdana"><a name="Figur5"><font size="2"></font></a> <font size="2"><img style="width: 566px; height: 339px;" alt="" src="/img/revistas/ruc/v26n2/2a09f5.JPG">    ]]></body>
<body><![CDATA[<br>     </font>     <small><small>    <font size="2">Figura 5. Muestra el ECG/VCG en el plano frontal comparativo de ambos trastornos dromotropos.&nbsp;    <br>     A pesar de que los dos poseen rotaci&oacute;n antihoraria y extremo desv&iacute;o del eje del QRS hacia la izquierda, son claras las diferencias entre ambos:    <br>     &middot; Vectores iniciales dirigidos para abajo y a la izquierda en el bloqueo fascicular superior de la rama derecha (BFSRD) y para abajo y a la derecha&nbsp;    <br>     &nbsp; en el bloqueo fascicular anterior izquierdo (BFAI).    <br>        &middot; Patr&oacute;n R o Rs en I y aVL en el BFSRD y qR en el BFAI.    <br>        &middot; SII &gt; SIII en el BFSRD y SII &lt; SIII en el BFAI.    <br>        &middot; R final prominente en aVR en el BFSRD y ausente o peque&ntilde;a en el BFAI.    <br>        &middot; RFCD localizado en el cuadrante superior derecho en el BFSRD y en el cuadrante superior izquierdo en el BFAI.</font></small></small></font></p>          <p></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Existen evidencias cl&iacute;nicas en humanos que apoyan la presencia de retardo  final de conducci&oacute;n (RFCD) como parte del proceso fisiopatol&oacute;gico del SBr  (mecanismo de despolarizaci&oacute;n). Los RFCD se localizan en el TSVD y podr&iacute;an  relacionarse con alg&uacute;n grado de anormalidad estructural </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b19"><font color="#1f1a17" face="Verdana"><sup>19</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".19"></a> (<a href="#Figur6">figura 6</a>).&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>          ]]></body>
<body><![CDATA[<p align="left"><font face="Verdana" size="2"><a name="Figur6"></a><img style="width: 566px; height: 365px;" alt="" src="/img/revistas/ruc/v26n2/2a09f6.JPG">    <br>     </font>     </p>          <p><font face="Verdana"><small><small><span style="font-weight: bold;"> <font size="2">Figura 6.</font></span><font size="2"> Se muestra la correlaci&oacute;n ECG/VCG en el PF del mismo paciente donde se constatan elementos que indican retardo final de conducci&oacute;n (RFCD) compatibles con BFSRD y no con BFAI. Los vectores de los 30 ms iniciales dirigidos para la izquierda, I y aVL muestran patr&oacute;n R y Rs (en el BFAI qR), y el RFCD est&aacute; localizado en el cuadrante superior derecho (en le BFAI en el cuadrante superior izquierdo), lo que justifica la onda R final prominente en aVR.</font></small></small></font></p>       <font face="Verdana" size="2">           <br>      </font>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> <b>DURACI&oacute;N DEL INTERVALO QRS&nbsp;</b> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> El intervalo QRS representa el tiempo de conducci&oacute;n intraventricular. En  un estudio reciente que incluy&oacute; a 200 pacientes con SBr, se comprob&oacute; que  la prolongaci&oacute;n del complejo QRS (</font><font color="#1f1a17" face="Century Schoolbook" size="2"><font color="#1f1a17" face="Verdana" size="2">&sup3; 120 ms) se observa m&aacute;s frecuentemente  en los sintom&aacute;ticos </font><font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b20"><font color="#1f1a17" face="Verdana"><sup>20</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".20"></a>.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>      <multicol gutter="18" cols="2"></multicol>     <p align="left"><font color="#1f1a17" face="Verdana" size="2"> La administraci&oacute;n de f&aacute;rmacos bloqueadores del canal de sodio produce en  las mujeres un incremento significativamente mayor del intervalo PR y de  la duraci&oacute;n del complejo QRS </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b3"><font color="#1f1a17" face="Verdana"><sup>3</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2">.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Ohkubo y colaboradores </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(<a href="#b21">21</a>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".21"></a> estudiaron la duraci&oacute;n de los intervalos PR,  QRS y QT en 35 pacientes con SBr (10 sintom&aacute;ticos y 25 asintom&aacute;ticos).  El QRS fue medido en V</font><font color="#1f1a17" face="Verdana"><sub>2</sub></font><font color="#1f1a17" face="Verdana" size="2">. Una duraci&oacute;n del QRS &sup3; 120 ms result&oacute; predictora  de arritmias y fue el &uacute;nico par&aacute;metro que diferenci&oacute; los sintom&aacute;ticos de  los asintom&aacute;ticos. Un intervalo r-J en V</font><font color="#1f1a17" face="Verdana"><sub>2 </sub></font> <font color="#1f1a17" face="Verdana" size="2">&sup3; 90 ms y una duraci&oacute;n del intervalo  QRS en V</font><font color="#1f1a17" face="Verdana"><sub>6</sub></font><font color="#1f1a17" face="Verdana" size="2"> &sup3; 90 ms son</font><font color="#ff0000" face="Verdana" size="2"> </font> <font color="#1f1a17" face="Verdana" size="2">predictores de recurrencias de eventos en pacientes  con SBr sintom&aacute;ticos </font><font color="#1f1a17" face="Verdana"><sup>(<a href="#b22">22</a>)</sup></font><font color="#1f1a17" face="Verdana" size="2">.<a name=".22"></a>&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>     <font face="Verdana" size="2">         <br>      </font>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> <b>CARACTER&iacute;STICAS MORFOL&oacute;GICAS DEL COMPLEJO QRS&nbsp;</b> </font></p>          ]]></body>
<body><![CDATA[<p align="left"><font color="#1f1a17" face="Verdana" size="2"> Desde la descripci&oacute;n inicial en 1992, se considera que el patr&oacute;n electrocardiogr&aacute;fico  del SBr presenta bloqueo incompleto (BIRD) o completo de rama derecha (BCRD).  No obstante, son frecuentes los casos donde este disturbio dromotr&oacute;pico  por el sistema hisiano derecho presenta caracter&iacute;sticas at&iacute;picas o no existe  por la ausencia de la indispensable onda S final ancha en las derivaciones  izquierdas I, aVL, V5 y V6 </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(<a href="#b23">23</a>,<a href="#b24">24</a>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".23"></a><a name=".24"></a>. Esta incongruencia ha dado lugar a  las confusas denominaciones de <i>bloqueo de rama derecha s&iacute;mil o seudo bloqueo  de rama derecha. </i>La <a href="#Figur7">figura 7</a> muestra un ejemplo de estos casos. Con el  objetivo de esclarecer esta diferencia, nuestro grupo realiz&oacute; un an&aacute;lisis  comparativo electrocardiogr&aacute;fico y vectorcardiogr&aacute;fico de pacientes con  SBr sintom&aacute;ticos y patr&oacute;n tipo 1 con individuos sanos portadores de los  patrones electrocardiogr&aacute;ficos de bloqueo completo e incompleto de rama  derecha. Nuestros resultados revelaron que los pacientes con SBr tienen  un patr&oacute;n de disturbio dromotropo diferente de aquel de los individuos  sanos con BIRD o BCRD lo que se&ntilde;ala que en la entidad el bloqueo en el  sistema hisiano derecho es divisional o fascicular y ocurre en las fibras  localizadas dentro del TSVD (bloqueo fascicular superior de la rama derecha)  </font><font color="#1f1a17" face="Verdana"><sup>(<a href="#b25">25</a>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".25"></a>.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>            <p><font face="Verdana"><a name="Figur7"><font size="2"></font></a> <font size="2"><img style="width: 566px; height: 348px;" alt="" src="/img/revistas/ruc/v26n2/2a09f7.JPG">    <br>    </font>    <small><small><span style="font-weight: bold;"><font size="2">Figura 7. </font> </span> <font size="2">ECG de un paciente portador de SBr con patr&oacute;n electrocardiogr&aacute;fico tipo 1 en ausencia de ondas S finales en las derivaciones izquierdas I,&nbsp;    <br>     aVL, V5 y V6. Este tipo de trazados ha motivado las confusas denominaciones de bloqueo de rama derecha s&iacute;mil o seudobloqueo de rama derecha.</font></small></small></font></p>          <p></p>       <multicol gutter="18" cols="2"></multicol>     <p align="left"><font color="#1f1a17" face="Verdana" size="2"> <b>FRAGMENTACI&oacute;N DEL COMPLEJO QRS&nbsp;</b> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Recientemente, Das y colaboradores </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b26"><font color="#1f1a17" face="Verdana"><sup>26</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".26"></a> describieron en pacientes con enfermedad  arterial coronaria la presencia de complejos QRS fragmentados. Relacionaron  este hallazgo con mayor n&uacute;mero de eventos y peor pron&oacute;stico.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> La fQRS es definida en el ECG de superficie por la presencia dentro de  un QRS no ancho (&lt;120ms) de ondas R primas (R&rsquo;) o muescas en el nadir de  la onda R o de la onda S, o la presencia de m&aacute;s de una onda R en dos derivaciones  contiguas (<a href="#Figur8">figura 8</a>).&nbsp; </font></p>           <p><font face="Verdana"><a name="Figur8"><font size="2"></font></a> <font size="2"><img style="width: 274px; height: 192px;" alt="" src="/img/revistas/ruc/v26n2/2a09f8.JPG">    <br>     </font>     <small><small><span style="font-weight: bold;"><font size="2">Figura 8</font></span><font size="2">. Presencia de fragmentaci&oacute;n del QRS (fQRS) (flechas) en dos&nbsp;    ]]></body>
<body><![CDATA[<br>     derivaciones consecutivas (V1-V2) en un paciente con SBr.</font></small></small></font></p>          <p></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> La fQRS en presencia de complejos QRS &sup3; 120 ms (bloqueos de rama, complejos  ventriculares prematuros o complejos estimulados) es definida tambi&eacute;n por  la presencia de dos o m&aacute;s muescas en las ondas R o S en por lo menos dos  derivaciones contiguas.&nbsp; </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> La fQRS se ha observado en pacientes con cardiopat&iacute;a no isqu&eacute;mica, enfermedad  de Chagas, displasia arritmog&eacute;nica del ventr&iacute;culo derecho, cardiopat&iacute;as  cong&eacute;nitas y en el SBr </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(<a href="#b27">27</a>-<a href="#b30">30</a>)</sup></font><font color="#1f1a17" face="Verdana" size="2">.<a name=".27"></a><a name=".28"></a><a name=".29"></a><a name=".30"></a>&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> En cualquier situaci&oacute;n, la fQRS traduce la activaci&oacute;n no homog&eacute;nea de ambos  ventr&iacute;culos debido a isquemia o escaras, y es un predictor de eventos arr&iacute;tmicos  y MS </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b27"><font color="#1f1a17" face="Verdana"><sup>27</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2">. En el SBr, Morita y colaboradores </font> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b31"><font color="#1f1a17" face="Verdana"><sup>31</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".31"></a> demostraron que el fQRS  es un marcador que puede predecir FV. Adicionalmente, los pacientes en  los que se demuestra la mutaci&oacute;n SCN5A presentan m&aacute;s frecuentemente fQRS.  Un retardo en la activaci&oacute;n epic&aacute;rdica del TSVD, expresada por el fQRS,  es un marcador de mal pron&oacute;stico en pacientes con SBr. El mapeo de superficie  corporal ha confirmado estos hallazgos </font> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b32"><font color="#1f1a17" face="Verdana"><sup>32</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".32"></a>.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>     <font face="Verdana" size="2">         <br>      </font>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> <b>EL &ldquo;SIGNO DE AVR&rdquo; Y SU SIGNIFICADO EN EL S&iacute;NDROME DE BRUGADA&nbsp;</b> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> El &ldquo;signo de aVR&rdquo; es definido como la presencia de una onda R </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana" size="2">&sup3; 3 mm o  un cociente R/q &sup3; 0,75 en la derivaci&oacute;n aVR y se lo ha asociado con un  incremento en el riesgo de arritmias ventriculares </font> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b33"><font color="#1f1a17" face="Verdana"><sup>33</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".33"></a> (<a href="#Figur9">figura 9</a>).&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>           <p><font face="Verdana"><a name="Figur9"><font size="2"></font></a> <font size="2"><img style="width: 274px; height: 113px;" alt="" src="/img/revistas/ruc/v26n2/2a09f9.JPG">    <br>     </font>     <small><small><span style="font-weight: bold;"><font size="2">Figura 9. </font> </span> <font size="2">Se observa en la derivaci&oacute;n aVR la presencia de onda R final con&nbsp;    ]]></body>
<body><![CDATA[<br>     voltaje prominente (&sup3; 3 mm) y un cociente R/q &sup3; 0,75 en un paciente portador&nbsp;    <br>     de SBr sintom&aacute;tico. La presencia de este signo es considerado un marcador de&nbsp;    <br>     mayor riesgo para el desarrollo de eventos arr&iacute;tmicos graves.</font></small></small></font></p>          <p></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Hipot&eacute;ticamente, el aumento en el voltaje de la onda R en aVR indica un  mayor retraso de la conducci&oacute;n ventricular en el TSVD y consecuentemente  mayor heterogenicidad el&eacute;ctrica.&nbsp; </font></p>       <multicol gutter="18" cols="2"></multicol>        <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Vectorcardiogr&aacute;ficamente, este retraso de la conducci&oacute;n ventricular se  localiza en el cuadrante superior derecho del plano frontal, correspondiente  al territorio de fasc&iacute;culo superior o subpulmonar de la rama derecha, anat&oacute;micamente  ubicada en la regi&oacute;n del TSVD </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(<a href="#b34">34</a>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".34"></a>.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>     <font face="Verdana" size="2">         <br>      </font>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> <b>REPOLARIZACI&oacute;N VENTRICULAR&nbsp;</b> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Desde el primer consenso </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b35"><font color="#1f1a17" face="Verdana"><sup>35</sup></font></a><font color="#1f1a17" face="Verdana"><sup><a name=".35"></a>)</sup></font><font color="#1f1a17" face="Verdana" size="2"> se describen en el SBr tres patrones electrocardiogr&aacute;ficos  de repolarizaci&oacute;n en las derivaciones precordiales derechas o derechas  altas, o ambas, denominados tipo 1, 2 y 3, presentando valor diagn&oacute;stico  s&oacute;lo el tipo 1. Las caracter&iacute;sticas de los patrones son las siguientes:&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>      <ul>            <li><font color="#1f1a17" face="Verdana" size="2"> Tipo 1: elevaci&oacute;n del punto J y segmento ST     </font><font color="#1f1a17" face="Century Schoolbook" size="2">   <font color="#1f1a17" face="Verdana" size="2">&sup3; 2 mm de convexidad superior  (<i>coved type</i>) o rectil&iacute;neo oblicuo descendente, seguido de onda T negativa  en V</font><font color="#1f1a17" face="Verdana"><sub>1</sub></font><font color="#1f1a17" face="Verdana" size="2">-V</font><font color="#1f1a17" face="Verdana"><sub>2</sub></font><font color="#1f1a17" face="Verdana" size="2"> o de V</font><font color="#1f1a17" face="Verdana"><sub>1 </sub></font>   <font color="#1f1a17" face="Verdana" size="2">a V</font><font color="#1f1a17" face="Verdana"><sub>3</sub></font><font color="#1f1a17" face="Verdana" size="2">.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2">     </font></li>            ]]></body>
<body><![CDATA[<li><font color="#1f1a17" face="Verdana" size="2"> Tipo 2: elevaci&oacute;n del segmento ST en su porci&oacute;n inicial     </font><font color="#1f1a17" face="Century Schoolbook" size="2">   <font color="#1f1a17" face="Verdana" size="2">&sup3; 2 mm y en la  final &sup3; 1 mm con perfil en silla de montar (<i>saddle back</i>) seguido de onda  T positiva o bif&aacute;sica en V</font><font color="#1f1a17" face="Verdana"><sub>1</sub></font><font color="#1f1a17" face="Verdana" size="2">-V</font><font color="#1f1a17" face="Verdana"><sub>2</sub></font><font color="#1f1a17" face="Verdana" size="2"> o de V</font><font color="#1f1a17" face="Verdana"><sub>1 </sub></font>   <font color="#1f1a17" face="Verdana" size="2">a V</font><font color="#1f1a17" face="Verdana"><sub>3</sub></font><font color="#1f1a17" face="Verdana" size="2">.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2">     </font></li>            <li><font color="#1f1a17" face="Verdana" size="2"> Tipo 3: elevaci&oacute;n del punto J y del segmento ST en silla de montar o de  convexidad superior en V</font><font color="#1f1a17" face="Century Schoolbook" size="2"><font color="#1f1a17" face="Verdana"><sub>1</sub></font><font color="#1f1a17" face="Verdana" size="2">-V</font><font color="#1f1a17" face="Verdana"><sub>2</sub></font><font color="#1f1a17" face="Verdana" size="2"> o de V</font><font color="#1f1a17" face="Verdana"><sub>1 </sub></font>   <font color="#1f1a17" face="Verdana" size="2">a V</font><font color="#1f1a17" face="Verdana"><sub>3</sub></font><font color="#1f1a17" face="Verdana" size="2">, = 2 mm en su porci&oacute;n inicial  y &lt; 1 mm en la final, seguido de onda T positiva (<a href="#Figur10">figura 10</a>).&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2">     </font></li>          </ul>           <p><font face="Verdana"><a name="Figur10"><font size="2"></font></a> <font size="2"><img style="width: 566px; height: 168px;" alt="" src="/img/revistas/ruc/v26n2/2a09f10.JPG">    <br>     </font>     <small><small><span style="font-weight: bold;"><font size="2">Figura 10.</font></span><font size="2"> Se muestran los tres tipos de patrones de repolarizaci&oacute;n en el SBr, donde solo el tipo 1 tiene valor diagn&oacute;stico cuando se asocia a&nbsp;    <br>     eventos (s&iacute;ncope o muerte s&uacute;bita abortada) en pacientes sin cardiopat&iacute;a estructural, efecto de drogas, insuficiencia coronaria o desequilibrio electrol&iacute;tico.</font></small></small></font></p>           <p align="left"><font color="#1f1a17" face="Verdana" size="2">Recientemente, en un modelo experimental, Take y colaboradores </font><font color="#1f1a17" face="Century Schoolbook" size="2">  <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b36"><font color="#1f1a17" face="Verdana"><sup>36</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".36"></a> describieron   un nuevo patr&oacute;n electrocardiogr&aacute;fico denominado patr&oacute;n Brugada tipo 0,   el cual se caracteriza por ser un patr&oacute;n tipo 1 pero sin onda T negativa.   En este estudio los autores demostraron que la conversi&oacute;n rec&iacute;proca entre   tipo 0 y tipo 1 se encuentra asociada a una significativa heterogenicidad   en los potenciales de acci&oacute;n monof&aacute;sicos, lo que es considerado un factor   predisponente para el desarrollo de arritmias ventriculares.&nbsp;</font></font></p>       <multicol gutter="18" cols="2"></multicol>        <p align="left"><font color="#1f1a17" face="Verdana" size="2"> El mecanismo molecular subyacente de la elevaci&oacute;n del segmento ST en el  patr&oacute;n electrocardiogr&aacute;fico Brugada, se relaciona con la salida de K</font><font color="#1f1a17" face="Century Schoolbook" size="2"><font color="#1f1a17" face="Verdana"><sup>+ </sup></font> <font color="#1f1a17" face="Verdana" size="2">durante  la fase 1 (canal I</font><font color="#1f1a17" face="Verdana"><sub>to</sub></font><font color="#1f1a17" face="Verdana" size="2">), coincidente con el punto J del ECG de superficie  y responsable de una marcada acentuaci&oacute;n de la muesca del potencial de  acci&oacute;n en el epicardio del TSVD, pero no en las c&eacute;lulas del endocardio.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> La onda J del SBr es originada por un gradiente de voltaje transmural en  el TSVD. Estas se registran con mayor sensibilidad en las derivaciones  precordiales derechas altas pudiendo no existir cuando el electrodo se  encuentra en la posici&oacute;n patr&oacute;n del cuarto espacio intercostal. Las derivaciones  accesorias derechas altas debieran realizarse en forma rutinaria ante la  sospecha de SBr, dado que numerosos trabajos han demostrado que aumentan  la sensibilidad para la detecci&oacute;n del patr&oacute;n electrocardiogr&aacute;fico diagn&oacute;stico  tipo 1 </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(<a href="#b37">37</a>-<a href="#b44">44</a>)</sup></font><font color="#1f1a17" face="Verdana" size="2">.</font><font color="#1f1a17" face="Verdana"><sup><a name=".37"></a><a name=".38"></a><a name=".39"></a><a name=".40"></a><a name=".41"></a><a name=".42"></a><a name=".43"></a><a name=".44"></a> </sup></font> <font color="#1f1a17" face="Verdana" size="2">De igual forma, Vatasescu y colaboradores </font> <font color="#1f1a17" face="Verdana"><sup>(<a href="#b45">45</a>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".45"></a> demostraron  que la inspiraci&oacute;n profunda pone en evidencia el patr&oacute;n electrocardiogr&aacute;fico  tipo 1 en el SBr por el mismo mecanismo que la colocaci&oacute;n de los electrodos  en una posici&oacute;n m&aacute;s alta. Durante el test provocativo con ajmalina las  derivaciones precordiales derechas altas V</font><font color="#1f1a17" face="Verdana"><sub>1H </sub></font> <font color="#1f1a17" face="Verdana" size="2">y V</font><font color="#1f1a17" face="Verdana"><sub>2H</sub></font><font color="#1f1a17" face="Verdana" size="2">, son las m&aacute;s sensibles  y espec&iacute;ficas para el diagn&oacute;stico del patr&oacute;n electrocardiogr&aacute;fico, mientras  que la V</font><font color="#1f1a17" face="Verdana"><sub>3H</sub></font><font color="#1f1a17" face="Verdana" size="2"> no muestra diferencias con la</font><font color="#0000ff" face="Verdana" size="2"> </font> <font color="#1f1a17" face="Verdana" size="2">V</font><font color="#1f1a17" face="Verdana"><sub>3</sub></font><font color="#1f1a17" face="Verdana" size="2"> convencional </font> <font color="#1f1a17" face="Verdana"><sup>(<a href="#b46">46</a>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".46"></a> (<a href="#Figur11">figura 11</a>).&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>           <p><font face="Verdana"><a name="Figur11"><font size="2"></font></a> <font size="2"><img style="width: 274px; height: 216px;" alt="" src="/img/revistas/ruc/v26n2/2a09f11.JPG">    ]]></body>
<body><![CDATA[<br>     </font>     <small><small><span style="font-weight: bold;"><font size="2">Figura 11.</font></span><font size="2"> Localizaci&oacute;n de las derivaciones precordiales derechas convencionales&nbsp;    <br>     (V1-V2 o de V1 a V3) y las accesorias o derivaciones precordiales derechas altas&nbsp;    <br>     (V1H, V2H y V3H). V1: 4&deg; espacio intercostal en el borde derecho del estern&oacute;n,&nbsp;    <br>     V2: 4&deg; espacio intercostal en el borde izquierdo del estern&oacute;n, V3: intermedia entre&nbsp;    <br>     V2 y V4, V1H: 2&deg; o 3&deg; espacio intercostal, en la margen derecha del estern&oacute;n,&nbsp;    <br>     V2H: 2&deg; o 3&deg; espacio intercostal, en la margen izquierda del estern&oacute;n.</font></small></small></font></p>          <p></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Al realizar el an&aacute;lisis electrocardiogr&aacute;fico ante la sospecha de un SBr,  deber&aacute;n ser excluidas numerosas condiciones que pueden simular el patr&oacute;n  tipo 1 caracter&iacute;stico, las denominadas formas adquiridas del SBr</font><font color="#1f1a17" face="Century Schoolbook" size="2"><font color="#1f1a17" face="Verdana"><sup> (</sup></font><a href="#b47"><font color="#1f1a17" face="Verdana"><sup>47</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2">,<a name=".47"></a>  patr&oacute;n electrocardiogr&aacute;fico Brugada-like </font> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#48"><font color="#1f1a17" face="Verdana"><sup>48</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".48"></a> o como nuestro grupo las  denomina <i>fenocopias de Brugada</i>. Fenocopia se define como una condici&oacute;n  ambiental que imita o copia una alteraci&oacute;n determinada gen&eacute;ticamente </font> <font color="#1f1a17" face="Verdana"><sup>(<a href="#b49">49</a>-<a href="#b51">5</a></sup></font><a href="#b51"><font color="#1f1a17" face="Verdana"><sup>1</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".49"></a><a name=".50"></a><a name=".51"></a>.  En la <a href="#t1">tabla 1</a> se muestran las fenocopias descriptas hasta el presente momento.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>      <font face="Verdana" size="2">      <a name="t1"></a><img style="width: 274px; height: 417px;" alt="" src="/img/revistas/ruc/v26n2/2a09t1.JPG">    <br>    </font>        <p align="left"><font color="#1f1a17" face="Verdana" size="2"> <b>PATR&oacute;N ELECTROCARDIOGR&aacute;FICO DESENMASCARADO POR F&aacute;RMACOS&nbsp;</b> </font></p>          ]]></body>
<body><![CDATA[<p align="left"><font color="#1f1a17" face="Verdana" size="2"> Dado que el patr&oacute;n tipo 1 puede temporalmente desaparecer transform&aacute;ndose  en los tipos 2 o 3, o incluso normalizar el ECG, como recurso se encuentran  las pruebas farmacol&oacute;gicas de provocaci&oacute;n. Para tal fin se emplean los  f&aacute;rmacos bloqueadores del canal de sodio </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(<a href="#b52">5</a></sup></font><a href="#b52"><font color="#1f1a17" face="Verdana"><sup>2</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".52"></a>. Los</font><font color="#0000ff" face="Verdana" size="2"> </font> <font color="#1f1a17" face="Verdana" size="2">protocolos utilizados  est&aacute;n esquematizados en la <a href="#t2">tabla 2</a>.&nbsp;</font></font></p>    <font face="Verdana" size="2">    <a name="t2"></a><img style="width: 275px; height: 239px;" alt="" src="/img/revistas/ruc/v26n2/2a09t2.JPG">    <br>    </font>        <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Se considera resultado positivo si luego de la prueba con alguno de estos  f&aacute;rmacos aparece el patr&oacute;n electrocardiogr&aacute;fico tipo 1. La prueba debe  realizarse con monitorizaci&oacute;n continua, en unidad de cuidados cr&iacute;ticos  y con recursos de resucitaci&oacute;n, registrando un ECG cada minuto durante  10 minutos. Deber&aacute; darse por concluida la prueba cuando: <i>a) </i>aparece el  patr&oacute;n ECG tipo 1 (diagn&oacute;stico confirmado); <i>b) </i>desarrollo de m&uacute;ltiples  extras&iacute;stoles o arritmias ventriculares complejas; <i>c) </i>aparece ensanchamiento  del QRS &gt; 130% respecto al valor basal</font><font color="#1f1a17" face="Century Schoolbook" size="2"><font color="#1f1a17" face="Verdana"><sup> (</sup></font><a href="#b53"><font color="#1f1a17" face="Verdana"><sup>53</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".53"></a>.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>       <multicol gutter="18" cols="2"></multicol>     <p align="left"><font color="#1f1a17" face="Verdana" size="2"> De todos los f&aacute;rmacos utilizados, la ajmalina es el m&aacute;s eficaz con una  sensibilidad de 80%, especificidad de 94,4%, valor predictivo positivo  de 93,3% y valor predictivo negativo de 82,9%</font><font color="#1f1a17" face="Century Schoolbook" size="2"><font color="#1f1a17" face="Verdana"><sup> (</sup></font><a href="#b54"><font color="#1f1a17" face="Verdana"><sup>54</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2">.<a name=".54"></a>&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> En un estudio realizado con flecainida en 110 pacientes con genotipo positivo,  se observ&oacute; que tiene un bajo valor predictivo negativo (36%)</font><font color="#1f1a17" face="Century Schoolbook" size="2"><font color="#1f1a17" face="Verdana"><sup> (</sup></font><a href="#b55"><font color="#1f1a17" face="Verdana"><sup>55</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".55"></a>.</font><font color="#1f1a17" face="Verdana"><sub>&nbsp;</sub></font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Los valores diagn&oacute;sticos de ajmalina y flecainida se compararon en un estudio  en el que 22 pacientes con diagn&oacute;stico confirmado de SBr se sometieron  sucesivamente a la prueba con ambos f&aacute;rmacos. La prueba confirm&oacute; el diagn&oacute;stico  en todos los pacientes cuando se administr&oacute; ajmalina, pero s&oacute;lo en 15 pacientes  cuando se utiliz&oacute; flecainida. Al mismo tiempo, la elevaci&oacute;n del segmento  ST-T fue mayor con ajmalina (0,43 &plusmn; 0,15 mV vs 0,29 &plusmn; 0,18 mV)</font><font color="#1f1a17" face="Century Schoolbook" size="2"><font color="#1f1a17" face="Verdana"><sup> (<a href="#b56">56</a>)</sup></font><font color="#1f1a17" face="Verdana" size="2">.<a name=".56"></a>&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>     <font face="Verdana" size="2">         <br>      </font>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> <b>INTERVALO QT&nbsp;</b> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Pitzalis y colaboradores </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b57"><font color="#1f1a17" face="Verdana"><sup>57</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".57"></a> describieron la prolongaci&oacute;n del intervalo  QT corregido (QTc) en precordiales derechas (pero no en las precordiales  izquierdas) en los pacientes con SBr, especialmente tras la administraci&oacute;n  de bloqueadores del sodio. Posteriormente esto se ha podido correlacionar  con un peor pron&oacute;stico, especialmente cuando la duraci&oacute;n del intervalo  QTc en V</font><font color="#1f1a17" face="Verdana"><sub>2</sub></font><font color="#1f1a17" face="Verdana" size="2"> es &sup3; 460 ms </font> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b58"><font color="#1f1a17" face="Verdana"><sup>58</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".58"></a>.</font><font color="#1f1a17" face="Verdana"><sup>&nbsp;</sup></font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Como el intervalo QT est&aacute; formado por la despolarizaci&oacute;n ventricular (QRS)  y la repolarizaci&oacute;n (ST/T), creemos que esta prolongaci&oacute;n selectiva representa  un cierto grado de bloqueo parietal en el TSVD, como el observado en la  displasia arritmog&eacute;nica del ventr&iacute;culo derecho (mecanismo de despolarizaci&oacute;n).&nbsp; </font></p>          ]]></body>
<body><![CDATA[<p align="left"><font color="#1f1a17" face="Verdana" size="2"> Antzelevitch y colaboradores </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b59"><font color="#1f1a17" face="Verdana"><sup>59</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)<a name=".59"></a></sup></font><font color="#1f1a17" face="Verdana" size="2"> identificaron una mutaci&oacute;n en los genes  CACNA1C (A39V y G490R) y CACNB2 (S481L) que codifican la subunidad alfa1  y beta2b del canal lento de calcio, voltaje sensible, con locus en el cromosoma  12, y que produce una p&eacute;rdida de la funci&oacute;n en la subunidad alfa-1C del  canal y que se manifiesta por el fenotipo electrocardiogr&aacute;fico del SBr  asociado a un intervalo QTc discretamente m&aacute;s corto (&pound; 360ms). Este intervalo  se mostr&oacute; con escasa adaptaci&oacute;n a las modificaciones de la frecuencia card&iacute;aca  y la quinidina normaliz&oacute; su duraci&oacute;n y previno la inducci&oacute;n de arritmias  ventriculares durante la estimulaci&oacute;n ventricular programada. A esta variante  se la conoce como SBr tipo 3.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>     <font face="Verdana" size="2">         <br>      </font>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> <b>INTERVALO TRANSCURRIDO DESDE EL &aacute;PICE HASTA EL FIN DE LA ONDA T (TPEAK-TEND  INTERVAL O TPE) Y RELACI&oacute;N DEL INTERVALO &aacute;PICE DE T/T-FIN/QT (TPEAK-TEND/QT  RATIO)&nbsp;</b> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> En electrocardiograf&iacute;a la onda T representa la repolarizaci&oacute;n ventricular.  El intervalo desde el inicio del complejo QRS hasta el v&eacute;rtice de la onda  T corresponde al per&iacute;odo refractario absoluto del potencial de acci&oacute;n monof&aacute;sico.&nbsp; </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> La rampa final descendente de la onda T de inscripci&oacute;n m&aacute;s r&aacute;pida que la  ascendente inicial corresponde al per&iacute;odo refractario relativo o vulnerable  del potencial de acci&oacute;n monof&aacute;sico.&nbsp; </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> El intervalo transcurrido desde el v&eacute;rtice hasta el final de la onda T  del ECG (T</font><font color="#1f1a17" face="Century Schoolbook" size="2"><font color="#1f1a17" face="Verdana"><sub>peak</sub></font><font color="#1f1a17" face="Verdana" size="2">/ T</font><font color="#1f1a17" face="Verdana"><sub>end</sub></font><font color="#1f1a17" face="Verdana" size="2"> interval or Tpe),</font><font color="#ff0000" face="Verdana" size="2"> </font> <font color="#1f1a17" face="Verdana" size="2">corresponde a la normal dispersi&oacute;n  transmural de la repolarizaci&oacute;n ventricular entre el epicardio, miocardio  medio y endocardio. La amplificaci&oacute;n de este intervalo (mayor heterogeneidad)  es un factor arritmog&eacute;nico funcional por reentrada en fase 2 y puede asociarse  con mayor tendencia a arritmias graves.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Este intervalo Tpe, inferido en V</font><font color="#1f1a17" face="Century Schoolbook" size="2"><font color="#1f1a17" face="Verdana"><sub>5</sub></font><font color="#1f1a17" face="Verdana" size="2">, tiene un valor normal de 94 ms en el  hombre y 92 ms en la mujer. La prolongaci&oacute;n del Tpe para valores &sup3; 120  ms se asocia con mayor probabilidad de evento arr&iacute;tmico en pacientes con  SBr </font><font color="#1f1a17" face="Verdana"><sup>(<a href="#b60">60</a>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".60"></a>.</font><font color="#1f1a17" face="Verdana"><sup>&nbsp;</sup></font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>       <multicol gutter="18" cols="2"></multicol>     <p align="left"><font color="#1f1a17" face="Verdana" size="2"> La principal ventaja de este par&aacute;metro Tpe obedece a que no est&aacute; influenciado  por la edad, el sexo o la frecuencia card&iacute;aca </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b61"><font color="#1f1a17" face="Verdana"><sup>61</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2">.<a name=".61"></a>&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> En individuos sanos, la relaci&oacute;n T</font><font color="#1f1a17" face="Century Schoolbook" size="2"><font color="#1f1a17" face="Verdana"><sub>peak</sub></font><font color="#1f1a17" face="Verdana" size="2">-T</font><font color="#1f1a17" face="Verdana"><sub>end</sub></font><font color="#1f1a17" face="Verdana" size="2">/QT tiene un valor medio de  21 ms en las derivaciones precordiales y permanece relativamente constante  entre frecuencias card&iacute;acas de 60 a 100 l/min.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> La relaci&oacute;n del intervalo pico de T / T-fin/QT o T</font><font color="#1f1a17" face="Century Schoolbook" size="2"><font color="#1f1a17" face="Verdana"><sub>peak</sub></font><font color="#1f1a17" face="Verdana" size="2">-T</font><font color="#1f1a17" face="Verdana"><sub>end</sub></font><font color="#1f1a17" face="Verdana" size="2">/QT es significativamente  mayor en los pacientes con riesgo de eventos arr&iacute;tmicos, como los portadores  del s&iacute;ndrome de QT prolongado, SBr, s&iacute;ndrome de QT corto, y en pacientes  con enfermedad coronaria. La reentrada funcional es el mecanismo subyacente  de la arritmog&eacute;nesis asociada con un aumento cociente T</font><font color="#1f1a17" face="Verdana"><sub>peak</sub></font><font color="#1f1a17" face="Verdana" size="2">-T</font><font color="#1f1a17" face="Verdana"><sub>end</sub></font><font color="#1f1a17" face="Verdana" size="2"> /QT y  a la vez es un marcador de inductibilidad en portadores de SBr </font> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b62"><font color="#1f1a17" face="Verdana"><sup>62</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".62"></a>.</font><font color="#1f1a17" face="Verdana"><sup>&nbsp;</sup></font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>     <font face="Verdana" size="2">         ]]></body>
<body><![CDATA[<br>      </font>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> <b>ARRITMIAS SUPRAVENTRICULARES&nbsp;</b> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> El SBr se acompa&ntilde;a, con relativa frecuencia (20 a 30% de los casos), de  arritmias auriculares siendo la fibrilaci&oacute;n auricular (FA), la m&aacute;s frecuente.&nbsp; </font></p>       <multicol gutter="18" cols="2"></multicol><font face="Verdana" size="2">    <br>      </font>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> <b>ARRITMIAS VENTRICULARES&nbsp;</b> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> La arritmia ventricular caracter&iacute;stica en el SBr es una TV de tipo polim&oacute;rfica,  extremadamente r&aacute;pida e iniciada por una extras&iacute;stole ventricular de similar  morfolog&iacute;a y con un intervalo de acoplamiento muy corto; la que eventualmente  degenera en FV y MS </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(<a href="#b65">65</a>-<a href="#69">69</a>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".65"></a><a name=".66"></a><a name=".67"></a><a name=".68"></a><a name=".69"></a>. La <a href="#Figur12">figura 12</a> muestra un ECG de 12 derivaciones  en un paciente con la mutaci&oacute;n SCN5A durante un evento de FV.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>           <p><font face="Verdana"><a name="Figur12"><font size="2"></font></a> <font size="2"><img style="width: 566px; height: 318px;" alt="" src="/img/revistas/ruc/v26n2/2a09f12.JPG">    <br>     </font>     <small><small><span style="font-weight: bold;"><font size="2">Figura 12</font></span><font size="2">. ECG de 12 derivaciones en un paciente con la mutaci&oacute;n SCN5A presente durante un evento de FV.</font></small></small></font></p>           <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Existen claras diferencias entre este tipo de TV polim&oacute;rfica y la descripta  como torsi&oacute;n de puntas (TdP) en el contexto de s&iacute;ndrome de QT prolongado  cong&eacute;nito o adquirido, las que se muestran en la <a href="#t3">tabla 3</a>.&nbsp;</font></p>    <font face="Verdana" size="2">    <a name="t3"></a><img style="width: 564px; height: 239px;" alt="" src="/img/revistas/ruc/v26n2/2a09t3.JPG">    <br>    </font>        ]]></body>
<body><![CDATA[<p align="left"><font color="#1f1a17" face="Verdana" size="2"> Las TV de tipo monom&oacute;rficas (TVM) son raras en el SBr. Estos casos han  sido descriptos asociados a cardiopat&iacute;a estructural del ventr&iacute;culo derecho  y con presencia de una mutaci&oacute;n homocigota en el gen SCN5A mediante la  utilizaci&oacute;n de distintos f&aacute;rmacos, por ejemplo, durante la prueba de ajmalina </font><font color="#1f1a17" face="Century Schoolbook" size="2">  <font color="#1f1a17" face="Verdana"><sup>(<a href="#b70">70</a>-<a href="#b77">77</a>)</sup></font><font color="#1f1a17" face="Verdana" size="2">.<a name=".70"></a><a name=".71"></a><a name=".72"></a><a name=".73"></a><a name=".74"></a><a name=".75"></a><a name=".76"></a><a name=".77"></a>&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Nuestro grupo recientemente report&oacute; el caso de un paciente con SBr, en  quien el aumento de la temperatura corporal desencaden&oacute; episodios de TVM  sostenida y repetitiva. La arritmia reci&eacute;n pudo controlarse con el descenso  de la temperatura </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b78"><font color="#1f1a17" face="Verdana"><sup>78</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".78"></a>.</font><font color="#1f1a17" face="Verdana"><sup>&nbsp;</sup></font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> La mayor&iacute;a de las arritmias ventriculares en el SBr acontecen t&iacute;picamente  durante el reposo o el sue&ntilde;o nocturno; demostr&aacute;ndose un significativo aumento  en la elevaci&oacute;n del segmento ST previo al inicio de TVP/FV, habi&eacute;ndose  establecido una relaci&oacute;n directamente proporcional entre el grado de elevaci&oacute;n  del segmento ST y el n&uacute;mero de episodios arr&iacute;tmicos </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(<a href="#b79">79</a>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".79"></a>.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> En condiciones normales existe una discreta heterogeneidad entre el epicardio  y el endocardio que se encuentra claramente aumentada en el SBr, lo que  conduce a anormalidades de la repolarizaci&oacute;n en el ECG que favorecen el  mecanismo por reentrada funcional en fase 2, responsable de la mayor&iacute;a  de las TV de la mayor&iacute;a de las canalopat&iacute;as </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b80"><font color="#1f1a17" face="Verdana"><sup>80</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".80"></a>.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>     <font face="Verdana" size="2">         <br>      </font>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> <b>FENOTIPOS AT&iacute;PICOS O VARIANTES DEL SBR&nbsp;</b> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Tambi&eacute;n denominados: fenotipo electrocardiogr&aacute;fico de Brugada at&iacute;pico y  fibrilaci&oacute;n ventricular idiop&aacute;tica asociada a patr&oacute;n de repolarizaci&oacute;n  precoz, y s&iacute;ndrome de Haissaguerre </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b81"><font color="#1f1a17" face="Verdana"><sup>81</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".81"></a>.</font><font color="#1f1a17" face="Verdana"><sup> </sup></font> <font color="#1f1a17" face="Verdana" size="2">Estas variantes se presentan en  pacientes sintom&aacute;ticos por s&iacute;ncope o MS abortada y manifiestan un fenotipo  electrocardiogr&aacute;fico similar al patr&oacute;n de Brugada tipo 1 pero localizado  en cara lateral, inferior o inferolateral y eventualmente asociado con  antecedentes familiares de MS, ausencia de cardiopat&iacute;a estructural, desequilibro  electrol&iacute;tico, f&aacute;rmacos, hipotermia o enfermedad coronaria </font> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b82"><font color="#1f1a17" face="Verdana"><sup>82</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".82"></a>.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>       <multicol gutter="18" cols="2"></multicol>     <p align="left"><font color="#1f1a17" face="Verdana" size="2"> A nuestro entender el patr&oacute;n electrocardiogr&aacute;fico tipo 1 presenta tres  subtipos electrocardiogr&aacute;ficos que denominamos subtipos 1A, 1B y 1C:&nbsp; </font></p>      <ul>            <li><font color="#1f1a17" face="Verdana" size="2"> Subtipo 1A: elevaci&oacute;n del punto J y segmento ST &sup3; 2 mm de convexidad superior  seguido de onda T negativa (<a href="#Figur13">figura 13</a>).&nbsp;     </font></li>            <li><font color="#1f1a17" face="Verdana" size="2"> Subtipo &nbsp;1B: elevaci&oacute;n del punto J y segmento ST &sup3; 2 mm rectil&iacute;neo oblicuo  descendente seguido de onda T negativa (<a href="#Figur14">figura 14</a>).&nbsp;     </font></li>            ]]></body>
<body><![CDATA[<li><font color="#1f1a17" face="Verdana" size="2"> Subtipo &nbsp;1C: elevaci&oacute;n del punto J y segmento ST     </font><font color="#1f1a17" face="Century Schoolbook" size="2">   <font color="#1f1a17" face="Verdana" size="2">&sup3; 2 mm en pared inferior,  lateral o inferolateral con un aspecto semejante a la letra griega lambda.  P&eacute;rez Riera y colaboradores </font><font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b82"><font color="#1f1a17" face="Verdana"><sup>82</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2"> reportaron el primer caso con el subtipo  1C en Am&eacute;rica del Sur. El patr&oacute;n electrocardiogr&aacute;fico fue denominado onda  lambda por Gussak y colaboradores </font><font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b84"><font color="#1f1a17" face="Verdana"><sup>84</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)<a name=".84"></a> </sup></font>   <font color="#1f1a17" face="Verdana" size="2">(<a href="#Figur15">figura 15</a>).&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2">     </font></li>          </ul>           <p><font face="Verdana" size="2"><a name="Figur13"></a><img style="width: 274px; height: 155px;" alt="" src="/img/revistas/ruc/v26n2/2a09f13.JPG">    <br>     </font>     <small><small><font face="Verdana" size="2"><span style="font-weight: bold;">Figura 13</span>. Patr&oacute;n electrocardiogr&aacute;fico Brugada subtipo 1A, caracterizado por elevaci&oacute;n&nbsp;    <br>     del punto J y segmento ST </font> <font color="#1f1a17" face="Century Schoolbook" size="2"><small><small> <font color="#1f1a17" face="Verdana" size="2">&sup3;</font></small></small></font><font face="Verdana" size="2"> 2 mm de convexidad superior, patr&oacute;n tipo &ldquo;Bull Terrier&rdquo;,&nbsp;    <br>     seguido de onda T negativa en precordiales derechas y/o precordiales derechas altas.</font></small></small></p>          <p><font face="Verdana"><a name="Figur14"><font size="2"></font></a> <font size="2"><img style="width: 274px; height: 155px;" alt="" src="/img/revistas/ruc/v26n2/2a09f14.JPG">    <br>     </font>     <small><small>   <span style="font-weight: bold;"><font size="2">Figura 14.</font></span><font size="2"> Patr&oacute;n electrocardiogr&aacute;fico Brugada subtipo 1B, caracterizado&nbsp;    <br>     por elevaci&oacute;n del punto J y segmento ST &sup3; 2mm rectil&iacute;neo oblicuo&nbsp;    <br>     descendente (no convexo hacia arriba) seguido de onda T negativa en&nbsp;    ]]></body>
<body><![CDATA[<br>     precordiales derechas y/o precordiales derechas altas.</font></small></small></font></p>          <p><font face="Verdana"><a name="Figur15"><font size="2"></font></a> <font size="2"><img style="width: 566px; height: 233px;" alt="" src="/img/revistas/ruc/v26n2/2a09f15.JPG">    <br>     </font>     <small><small>   <span style="font-weight: bold;"><font size="2">Figura 15.</font></span><font size="2"> Patr&oacute;n electrocardiogr&aacute;fico Brugada subtipo 1C, caracterizado por el segmento ST elevado &sup3; 2 mm (0,2 mV), triangular o de&nbsp;    <br>     convexidad&nbsp;superior seguido por onda T negativa en pared inferior y/ o lateral. Denominado &ldquo;onda lambda&rdquo; por su semejanza con la letra griega</font></small></small></font></p>           <p align="left"><font color="#1f1a17" face="Verdana" size="2">El trazado presentaba elevaci&oacute;n persistente del segmento ST en las derivaciones   inferiores con imagen rec&iacute;proca o especular en la cara anterior y que no   se modific&oacute; con la utilizaci&oacute;n de nitrito sublingual (<a href="#Figur16">figura 16</a>).&nbsp; </font></p>       <font face="Verdana" size="2">       <a name="Figur16"></a><img style="width: 566px; height: 233px;" alt="" src="/img/revistas/ruc/v26n2/2a09f16.JPG">    <br>      </font>          <p><font face="Verdana"><small><small><span style="font-weight: bold;"> <font size="2">Figura 16.</font></span><font size="2"> ECG de un paciente masculino de origen asi&aacute;tico con episodios sincopales y antecedentes familiares de muerte s&uacute;bita. Se observa la onda    <br>     lambda, caracterizada por una elevaci&oacute;n del segmento ST de perfil triangular o de convexidad superior &sup3; 2 mm (0,2 mV), seguido de onda T negativa&nbsp;    <br>     en pared inferior y apical (V6) en ausencia de hipotermia, desequilibrios electrol&iacute;ticos o isquemia. Se evidencia imagen rec&iacute;proca o en espejo de V1 a V3.</font></small></small></font></p>          <p></p>      <multicol gutter="18" cols="2"></multicol>     ]]></body>
<body><![CDATA[<p align="left"><font color="#1f1a17" face="Verdana" size="2"> Se logr&oacute; registrar mediante un Holter de 24&nbsp;h un episodio de TVP iniciada  por una extras&iacute;stole con un intervalo de acoplamiento muy corto con fen&oacute;meno  de R/T, y que degener&oacute; en FV y luego asistolia (<a href="#Figur17">figura 17</a>).&nbsp; </font></p>           <p><font face="Verdana"><a name="Figur17"><font size="2"></font></a> <font size="2"><img style="width: 566px; height: 126px;" alt="" src="/img/revistas/ruc/v26n2/2a09f17.JPG">    <br>     </font>     <small><small><span style="font-weight: bold;"><font size="2">Figura 17.</font></span><font size="2">Registro Holter de 24 h del mismo paciente. Durante la etapa de sue&ntilde;o nocturno se evidencia espont&aacute;neamente un episodio de taquicardia&nbsp;    <br>     ventricular polim&oacute;rfica que degenera en fibrilaci&oacute;n ventricular y asistolia. Obs&eacute;rvese c&oacute;mo la extras&iacute;stole que precipita el evento presenta un intervalo&nbsp;    <br>     de acoplamiento extremamente corto.</font></small></small></font></p>           <p align="left"><font color="#1f1a17" face="Verdana" size="2"> El patr&oacute;n 1C de repolarizaci&oacute;n ha sido observado en el infarto agudo de  miocardio por Kukla y colaboradores </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b85"><font color="#1f1a17" face="Verdana"><sup>85</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2">.<a name=".85"></a> Estos autores postulan que el  patr&oacute;n Lambda-like ST puede ser un nuevo marcador de riesgo en infarto  agudo con elevaci&oacute;n del segmento ST. El patr&oacute;n de repolarizaci&oacute;n precoz  es un hallazgo com&uacute;n entre atletas j&oacute;venes el cual se asocia con frecuencia  a criterios de voltaje de hipertrofia ventricular izquierda observado predominantemente  en el sexo masculino y con prevalencia mayor entre atletas afrodescendientes  </font><font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b86"><font color="#1f1a17" face="Verdana"><sup>86</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2">.<a name=".86"></a> Tanto el SBr como el patr&oacute;n de repolarizaci&oacute;n precoz son mucho m&aacute;s  frecuentes en el sexo masculino, sugiri&eacute;ndose un importante rol de la testosterona  en la repolarizaci&oacute;n ventricular en ambos </font> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b87"><font color="#1f1a17" face="Verdana"><sup>87</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".87"></a>.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Estudios previos se&ntilde;alan que el patr&oacute;n repolarizaci&oacute;n precoz caracterizado  por elevaci&oacute;n del punto J y segmento ST </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana" size="2">&sup3; 0,1 mV en por lo menos dos derivaciones  contiguas asociado a muescas en la rampa descendente de la R y elevaci&oacute;n  del segmento ST en la pared lateral (V</font><font color="#1f1a17" face="Verdana"><sub>4</sub></font><font color="#1f1a17" face="Verdana" size="2"> a V</font><font color="#1f1a17" face="Verdana"><sub>6</sub></font><font color="#1f1a17" face="Verdana" size="2">) y/o inferior (II, III, aVF),  no siempre es benigno </font><font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b88"><font color="#1f1a17" face="Verdana"><sup>88</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2">.<a name=".88"></a> Recientemente, Haruta y colaboradores </font> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b89"><font color="#1f1a17" face="Verdana"><sup>89</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2">  <a name=".89"></a>observaron que este patr&oacute;n se asocia a elevado riesgo de MS e inesperada  en la poblaci&oacute;n asi&aacute;tica.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Tikkanen y colaboradores </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b90"><font color="#1f1a17" face="Verdana"><sup>90</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2"> <a name=".90"></a>observan que los patrones fenot&iacute;picos electrocardiogr&aacute;ficos  de repolarizaci&oacute;n precoz son &uacute;tiles para clasificar a individuos de mediana  edad con y sin riesgo de MS arr&iacute;tmica. De esta forma, la presencia de un  r&aacute;pido ascenso del segmento ST despu&eacute;s del punto J parece ser una variante  benigna de repolarizaci&oacute;n precoz observada con frecuencia en atletas sanos.  Contrariamente</font><font color="#0000ff" face="Verdana" size="2">,</font><font color="#1f1a17" face="Verdana" size="2"> los sujetos con patr&oacute;n de repolarizaci&oacute;n precoz con segmento  ST horizontal y descendente presentan un mayor riesgo de MS. Adem&aacute;s, cuando  este patr&oacute;n</font><font color="#0000ff" face="Verdana" size="2"> </font> <font color="#1f1a17" face="Verdana" size="2">de repolarizaci&oacute;n precoz presenta elevaci&oacute;n del segmento ST  (&sup3;</font><font color="#0000ff" face="Verdana" size="2"> </font> <font color="#1f1a17" face="Verdana" size="2">0,2 mV) el riesgo relativo de muerte por arritmia aument&oacute; significativamente.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> El patr&oacute;n de repolarizaci&oacute;n precoz muestra alguna evidencia de base hereditaria  en la poblaci&oacute;n general, lo que justificar&iacute;a la realizaci&oacute;n de estudios  gen&eacute;ticos </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(<a href="#b91">91</a>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".91"></a>.</font><font color="#1f1a17" face="Verdana"><sup> </sup></font> <font color="#1f1a17" face="Verdana" size="2">Esta aseveraci&oacute;n debe ser tomada con cautela hasta que  estudios de cohorte mayores est&eacute;n disponibles.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> El canal de calcio card&iacute;aco tipo L (LTCC) juega un papel importante en  el funcionamiento el&eacute;ctrico y mec&aacute;nico del coraz&oacute;n. Las mutaciones en los  genes CACNA1C (subunidad alfa del canal de calcio tipo-L conocido como<i>  </i>CaV1.2) y CACNB2 (subunidad beta-2 voltaje dependiente del canal de calcio  tipo-L), constituyen uno de los varios canales que transportan calcio dentro  de las c&eacute;lulas y est&aacute;n asociadas a una serie de s&iacute;ndromes arr&iacute;tmicos card&iacute;acos  hereditarios, entre ellos el s&iacute;ndrome de Timothy, los tipos 3 y 4 del SBr,  y la repolarizaci&oacute;n precoz. La identificaci&oacute;n gen&eacute;tica de estos s&iacute;ndromes  ha conducido a una mejor comprensi&oacute;n de los mecanismos moleculares y celulares,  lo que permitir&aacute; el desarrollo de nuevos enfoques terap&eacute;uticos de las manifestaciones  arr&iacute;tmicas de estas entidades </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(<a href="#b92">92</a>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".92"></a>.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>          ]]></body>
<body><![CDATA[<p align="left"><font color="#1f1a17" face="Verdana" size="2"> Reinhard y colaboradores </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b93"><font color="#1f1a17" face="Verdana"><sup>93</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".93"></a> han demostrado que el fenotipo electrocardiogr&aacute;fico  de repolarizaci&oacute;n precoz puede ser hereditario. Hijos de padres con este  patr&oacute;n tienen 2,5 veces m&aacute;s chances de presentarlo en sus respectivos ECG.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>       <multicol gutter="18" cols="2"></multicol>     <p align="left"><font color="#1f1a17" face="Verdana" size="2"> <b>ESTRATIFICACI&oacute;N DEL RIESGO MEDIANTE EL USO DEL ELECTROCARDIOGRAMA&nbsp;</b> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Para identificar a los pacientes de alto riesgo, Atarashi y Ogawa </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(<a href="#b94">94</a>)</sup></font><font color="#1f1a17" face="Verdana" size="2"><a name=".94"></a>  examinaron 60 ECG de pacientes con SBr procedentes del registro japon&eacute;s.  Los par&aacute;metros analizados fueron la duraci&oacute;n de la onda S en V</font><font color="#1f1a17" face="Verdana"><sub>1</sub></font><font color="#1f1a17" face="Verdana" size="2">, medida  desde el nadir al v&eacute;rtice de la siguiente r o r&rsquo; y la elevaci&oacute;n del segmento  ST en V</font><font color="#1f1a17" face="Verdana"><sub>2</sub></font><font color="#1f1a17" face="Verdana" size="2"> medido a 80 ms del punto J. Los autores verificaron que en los  pacientes que presentaron FV (n=17), la duraci&oacute;n de la onda S fue significativamente  mayor en V</font><font color="#1f1a17" face="Verdana"><sub>1</sub></font><font color="#1f1a17" face="Verdana" size="2"> as&iacute; como la elevaci&oacute;n del segmento ST en V</font><font color="#1f1a17" face="Verdana"><sub>2</sub></font><font color="#1f1a17" face="Verdana" size="2">. Una duraci&oacute;n de  la onda S &sup3; 80 ms en V</font><font color="#1f1a17" face="Verdana"><sub>1</sub></font><font color="#1f1a17" face="Verdana" size="2">, present&oacute; un valor predictivo positivo de 40,5%  y valor predictivo negativo de</font><font color="#1f1a17" face="Verdana"><sub> </sub></font> <font color="#1f1a17" face="Verdana" size="2">100% para la aparici&oacute;n de FV, con 100% de  sensibilidad.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> La elevaci&oacute;n del segmento ST &sup3; 0,18 mV present&oacute; un valor predictivo positivo  de 37,8% y un valor predictivo negativo de 100% para FV, con 100% de sensibilidad.  Ambos par&aacute;metros fueron indicadores altamente espec&iacute;ficos de alto riesgo  para el desarrollo de FV.&nbsp; </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> Makimoto y colaboradores </font><font color="#1f1a17" face="Century Schoolbook" size="2"> <font color="#1f1a17" face="Verdana"><sup>(</sup></font><a href="#b95"><font color="#1f1a17" face="Verdana"><sup>95</sup></font></a><font color="#1f1a17" face="Verdana"><sup>)<a name=".95"></a> </sup></font> <font color="#1f1a17" face="Verdana" size="2">observaron, en pacientes con SBr, que durante  la etapa de recuperaci&oacute;n en la prueba de esfuerzo, la elevaci&oacute;n del ST-T  fue un factor predictor significativo para el desarrollo de eventos card&iacute;acos  graves, especialmente cuando el paciente era sintom&aacute;tico (presente en m&aacute;s  de 50% de los casos).&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>     <font face="Verdana" size="2">         <br>      </font>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> <b>CONCLUSIONES&nbsp;</b> </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> El electrocardiograma de 12 derivaciones asociado a las derivaciones accesorias  paraesternales altas es un recurso que aporta fundamental informaci&oacute;n diagn&oacute;stica  y pron&oacute;stica en los pacientes con SBr. Con este m&eacute;todo simple, econ&oacute;mico,  reproducible y operador independiente pueden ser estudiadas alteraciones  de la despolarizaci&oacute;n y repolarizaci&oacute;n, como la prolongaci&oacute;n de la onda  P, de los intervalos PR o PQ, QRS, QT/QTc, la eventual presencia de fQRS  y del signo de aVR, los disturbios de conducci&oacute;n de la rama derecha as&iacute;  como el grado de elevaci&oacute;n del punto J, segmento ST, polaridad de la onda  T, la rara presencia de macro y microalternancia de la onda T, el intervalo  transcurrido desde el &aacute;pice hasta el fin de la onda T, as&iacute; como la relaci&oacute;n  del intervalo &aacute;pice de T-Tfin/QT. El ECG permite adem&aacute;s diagnosticar los  frecuentes episodios de fibrilaci&oacute;n auricular y otras arritmias supraventriculares  as&iacute; como caracterizar las diversas taquiarritmias ventriculares.&nbsp; </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"> El conocimiento de las distintas manifestaciones el&eacute;ctricas en el SBr como  as&iacute; tambi&eacute;n los diagn&oacute;sticos diferenciales que deben plantearse, contribuir&aacute;n  sin dudas a un mejor y m&aacute;s r&aacute;pido manejo de nuestros pacientes. El aprendizaje</font><font color="#1f1a17" face="Century Schoolbook" size="2"><font color="#ff0000" face="Verdana" size="2">  </font><font color="#1f1a17" face="Verdana" size="2">de estos patrones infrecuentes debe ser estimulado en todos aquellos que  intervengan en el cuidado de pacientes.&nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>     <font face="Verdana" size="2">         <br>      </font>          ]]></body>
<body><![CDATA[<p align="left"><font color="#1f1a17" face="Verdana" size="2"> <b>REFERENCIAS&nbsp;</b> </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b1"></a> <a href="#.1">1</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Benito B, Brugada R, Brugada J, Brugada P.</b> Brugada syndrome. Prog Cardiovasc  Dis 2008; 51: 1-22.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b2"></a> <a href="#.2">2</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Juang JM, Huang SK.</b> Brugada syndrome: an under recognized electrical  disease in patients with sudden card&iacute;ac death. Cardiology 2004; 101: 157-69.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b3"></a> <a href="#.3">3</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Benito B, Sarkozy A, Mont L, Henkens S, Berruezo A, Tamborero D, et al.</b>  Gender differences in clinical manifestations of Brugada syndrome. J Am  Coll Cardiol 2008; 52: 1567-73.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b4"></a> <a href="#.4">4</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Oreto G, Corrado D, Delise P, Fedele F, Gaita F, Gentile F, et al.</b> Doubts  of the cardiologist regarding an electrocardiogram presenting QRS V1-V2  complexes with positive terminal wave and ST segment elevation. Consensus  Conference promoted by the Italian Cardiology Society. G Ital Cardiol (Rome)  2010; 11(Suppl 2): 3S-22S.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b5"></a> <a href="#.5">5</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Smits JP, Koopmann TT, Wilders R, Veldkamp MW, Opthof T, Bhuiyan ZA,  et al.</b> A mutation in the human card&iacute;ac sodium channel (E161K) contributes  to sick sinus syndrome, conduction disease and Brugada syndrome in two  families. J Mol Cell Cardiol 2005; 38: 969-81.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b6"></a> <a href="#.6">6</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Sumiyoshi M, Nakazato Y, Tokano T, Yasuda M, Mineda Y, Nakata Y, et al.</b>  Sinus node dysfunction concomitant with Brugada syndrome. Circ J 2005;  69: 946-50.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b7"></a> <a href="#.7">7</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Fazelifar AF, Haghjoo M, Emkanjoo Z, Alizadeh A, Alasti M, Peighambari  M, et al.</b> Brugada-type ECG association with unexpected sick sinus syndrome.  Pacing Clin Electrophysiol 2006; 29: 204-6.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="8"></a> <a href="#.8">8</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Wilde AA, Brugada R.</b> Phenotypical manifestations of mutations in the  genes encoding subunits of the cardiac sodium channel. Circ Res 2011; 108:  884-97.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b9"></a> <a href="#.9">9</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Bezzina C, Veldkamp MW, van Den Berg MP, Postma AV, Rook MB, Viersma  JW, et al.</b> A single Na(+) channel mutation causing both long-QT and Brugada  syndromes. Circ Res; 85: 1206-13.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b10"></a> <a href="#.10">10</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Neu A, Eiselt M, Paul M, Sauter K, Stallmeyer B, Isbrandt D, et al.</b>  A homozygous SCN5A mutation in a severe, recessive type of card&iacute;ac conduction  disease. Hum Mutat 2010; 1609-21.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b11"></a> <a href="#.11">11</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Hayashi H, Sumiyoshi M, Yasuda M, Komatsu K, Sekita G, Kawano Y, et  al.</b> Prevalence of the Brugada-type electrocardiogram and incidence of Brugada  syndrome in patients with sick sinus syndrome. Circ J 2010; 74: 271-7.    &nbsp; </font></p>       <multicol gutter="18" cols="2"></multicol>     <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b12"></a> <a href="#.12">12</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Letsas KP, Weber R, Astheimer K, Mihas CC, Stockinger J, Blum T, et  al.</b> Predictors of atrial tachyarrhythmias in subjects with type 1 ECG pattern  of Brugada syndrome. Pacing Clin Electrophysiol 2009; 32: 500-5.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b13"></a> <a href="#.13">13</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Furukawa Y, Yamada T, Okuyama Y, Morita T, Tanaka K, Iwasaki Y, et al.</b>  Increased Intraatrial Conduction Abnormality Assessed by P-Wave Signal-Averaged  Electrocardiogram in Patients with Brugada Syndrome. Pacing Clin Electrophysiol  2011 (In Press).    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b14"></a> <a href="#.14">14</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Meregalli PG, Ruijter JM, Hofman N, Bezzina CR, Wilde AA, Tan HL.</b> Diagnostic  value of flecainide testing in unmasking SCN5A-related Brugada syndrome.  J Cardiovasc Electrophysiol 2006;17: 857-64.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b15"></a> <a href="#.15">15</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Smits JP, Eckardt L, Probst V, Bezzina CR, Schott JJ, Temme CA, et al</b>.  Genotype-phenotype relationship in Brugada syndrome: electrocardiographic  features differentiate SCN5A-related patients from non-SCN5A-related patients.  J Am Coll Cardiol 2002; 40: 350-6.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b16"></a> <a href="#.16">16</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Miyamoto A, Hayashi H, Makiyama T, Yoshino T, Mizusawa Y, Sugimoto Y,  et al.</b> Risk determinants in individuals with a spontaneous type 1 Brugada  ECG. Circ J 2011; 75: 844-51.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b17"></a> <a href="#.17">17</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Pastore CA, Moffa PJ, Spiritus MO, Tobias NM, de Moraes AP, Del Nero  Junior E, et al.</b> Fascicular blocks of the right branch. Standardization  of vectorelectrocardiographic findings. Arq Bras Cardiol 1983; 41: 161-6.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b18"></a> <a href="#.18">18.</a>&nbsp;&nbsp;&nbsp;&nbsp;<b>P&eacute;rez Riera AR, Ferreira C, Schapachnik E. </b>Value of 12 leads electrocardiogram  and derived methodologies in the diagnosis of Brugada disease. In: Antzelevitch  Ch, Brugada P, Brugada J, Brugada R. The Brugada Syndrome From Bench to  Bedside. &nbsp;Oxford: Blackwell Science;2005:87-110&nbsp;     </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b19"></a> <a href="#.19">19</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Coronel R, Casini S, Koopmann TT, Wilms-Schopman FJ, Verkerk AO, de  Groot JR, et al.</b> Right ventricular fibrosis and conduction delay in a patient  with clinical signs of Brugada syndrome: a combined elctrophysiological,  genetic, histopathologic, and computational study. Circulation 2005; 112:  2769-77.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b20"></a> <a href="#.20">20</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Junttila MJ, Brugada P, Hong K, Lizotte E, De Zutter M, Sarkozy A, et  al.</b> Differences in 12-lead electrocardiogram between symptomatic and asymptomatic  Brugada syndrome patients. J Cardiovasc Electrophysiol 2007; 19: 380-3.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b21"></a> <a href="#.21">21</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Ohkubo K, Watanabe I, Okumura Y, Ashino S, Kofine M, Nagashima K, et  al.</b> Prolonged QRS duration in lead V2 and risk of life-threatening ventricular  Arrhythmia in patients with Brugada syndrome. Int Heart J 2011; 52: 98-102.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b22"></a> <a href="#.22">22</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Takagi M, Yokoyama Y, Aonuma K, Aihara N, Hiraoka M; for the Japan Idiopathic  Ventricular Fibrillation Study (J-IVFS) Investigators. </b>Clinical characteristics  and risk stratification in symptomatic and asymptomatic patients with Brugada  syndrome: multicenter study in Japan. J Cardiovasc Electrophysiol 2007;  18: 1244-51.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b23"></a> <a href="#.23">23</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Gussak I, Antzelevitch C, Bjerregaard P, Towbin JA, Chaitman BR.</b> The  Brugada syndrome: clinical, electrophysiologic and genetic aspects. J Am  Coll Cardiol 1999; 33: 5-15.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b24"></a> <a href="#.24">24</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Rolf S, Haverkamp W, Eckardt L.</b> True Right Bundle Branch Block Masking  the Typical ECG in Brugada Syndrome. Pacing Clin Electrophysiol 2005; 28:  258-9.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b25"></a> <a href="#.25">25</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>P&eacute;rez Riera AR, Ferreira M, Hopman WM, McIntyre WF,</b> Baranchuk A. Electrovectorcardiographic  characterization of the type-1 Brugada ECG pattern [Abstract]. Europace.  In press 2011&nbsp;     </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b26"></a> <a href="#.26">26</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Das MK, Khan B, Jacob S, Kumar A, Mahenthiran J.</b> Significance of a fragmented  QRS complex versus a Q wave in patients with coronary artery disease. Circulation  2006; 113: 2495&ndash;501.&nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b27"></a> <a href="#.27">27</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Das MK, Maskoun W, Shen C, Michael MA, Suradi H, Desai M, et al.</b> Fragmented  QRS on twelve-lead electrocardiogram predicts arrhythmic events in patients  with ischemic and nonischemic cardiomyopathy. Heart Rhythm 2010; 7: 74-80.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="28"></a><a href="#.28"> 28</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Saumarez RC, Chojnowska L, Derksen R, Pytkowski M, Sterlinski M, Huang  CL, et al.</b> Sudden death in noncoronary heart disease is associated with  delayed paced ventricular activation. Circulation 2003; 107: 2595-600.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="29"></a> <a href="#.29">29</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Baranchuk A, Femen&iacute;a F, L&oacute;pez Diez JC, Muratore C, Valentino M, Retyk  E, et al.</b> Fragmented ECG in Chagas&rsquo; Cardiomyopathy (FECHA Study) [Abstract].Cardiol  J. In Press 2011.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b30"></a> <a href="#.30">30</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Peters S, Tr&uuml;mmel M, Koehler B.</b> QRS fragmentation in standard ECG as  a diagnostic marker of arrhythmogenic right ventricular dysplasia-cardiomyopathy.  Heart Rhythm 2008; 5: 1417-21.    &nbsp; </font></p>          ]]></body>
<body><![CDATA[<!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b31"></a> <a href="#.31">31</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Morita H, Kusano KF, Miura D, Nagase S, Nakamura K, Morita ST, et al.</b>  Fragmented QRS as a marker of conduction abnormality and a predictor of  prognosis of Brugada syndrome. Circulation 2008; 118: 1697-704.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b32"></a> <a href="#.32">32</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Morita H, Zipes DP, Wu J.</b> Brugada syndrome: insights of ST elevation,  arrhythmogenicity, and risk stratification from experimental observations.  Heart Rhythm 2009; 6: S34-43.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b33"></a><a href="#.33"> 33</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Babai Bigi MA, Aslani A, Shahrzad S.</b> aVR sign as a risk factor for life-threatening  arrhythmic events in patients with Brugada syndrome. Heart Rhythm 2007;  4: 1009-12.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b34"></a><a href="#.34"> 34</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Riera AR, Ferreira C, Ferreira Filho C, Dubner S, Barbosa Barros R,  Femen&iacute;a F, et al.</b> Clinical value of lead aVR. Ann Noninvasive Electrocardiol  2011; 16: 295-302.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b35"></a><a href="#.35"> 35</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Wilde AA, Antzelevitch C, Borggrefe M, Brugada J, Brugada R, Brugada  P, et al. </b>Study Group on the Molecular Basis of Arrhythmias of the European  Society of Cardiology Proposed diagnostic criteria for the Brugada syndrome:  consensus report. Circulation 2002; 106: 2514-9.    &nbsp; </font></p>       <multicol gutter="18" cols="2"></multicol>     ]]></body>
<body><![CDATA[<!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b36"></a> <a href="#.36">36</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Take Y, Morita H, Wu J, Nagase S, Morita S, Toh N, et al. </b>Spontaneous  electrocardiogram alterations predict ventricular fibrillation in Brugada  syndrome. Heart Rhythm. In Press 2011.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b37"></a> <a href="#.37">37</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Farre J.</b> The Brugada syndrome: Do we need more than the 12-lead ECG?  Eur Heart J 2000; 21: 264-5.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="38"></a> <a href="#.38">38</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Sangwatanaroj S, Prechawat S, Sunsaneewitayakul B, Sitthisook S, Tosukhowong  P, Tunsanga K.</b> Right ventricular electrocardiographic leads for detection  of Brugada syndrome in sudden unexplained death syndrome survivors and  their relatives. Clin Cardiol 2001; 24: 776-81.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="39"></a> <a href="#.39">39</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Sangwatanaroj S, Prechawat S, Sunsaneewitayakul B, Sitthisook S, Tosukhowong  P, Tunsanga K.</b> New electrocardiographic leads and the procainamide test  for the detection of the Brugada sign in sudden unexplained death syndrome  survivors and their relatives. Eur Heart J 2001; 22: 2290-6.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="40"></a> <a href="#.40">40</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Nagatomo T, Abe H, Oginosawa Y, Araki M, Nakashima Y. </b>Reproduction of  typical electrocardiographic findings of the Brugada syndrome using modified  precordial leads. J UOEH 2002; 24: 383-9.    &nbsp; </font></p>          ]]></body>
<body><![CDATA[<!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="41"></a> <a href="#.41">41</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Nagase S, Kusano KF, Morita H, Fujimoto Y, Kakishita M, Nakamura K,  et al.</b> Epicardial electrogram of the right ventricular outflow tract in  patients with the brugada syndrome. Using the epicardial lead. J Am Coll  Cardiol 2002; 39: 1992-5.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="42"></a><a href="#.42"> 42</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Takagi M, Toda I, Takeuchi K, Yoshikawa J.</b> Utility of right precordial  leads at higher intercostal space positions to diagnose Brugada syndrome.  Pacing Clin Electrophysiol 2002; 25: 241-2.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="43"></a> <a href="#.43">43</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Cabezon Ruiz S, Errazquin Saenz De Tejada F, Pedrote Mart&iacute;nez A, Mor&aacute;n  Risco JE, Mar&iacute;n Morgado J, et al.</b> Normal Conventional Electrocardiogram  with Negative Pharmacological Stress Test does Not Rule out Brugada Syndrome.  Rev Esp Cardiol 2003; 56: 107-10.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b44"></a><a href="#.44"> 44</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Butz T, Vogt J, Vielhauer C, Welzel U, Langer C, Horstkotte D.</b> Detection  of a type 1 Brugada ECG by ECG recording at a higher intercostal space  of leads V(1) and V (2). Herz 2010; 35: 112.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b45"></a> <a href="#.45">45</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Vatasescu RG, Dan M, Dorobantu M. </b>Deep inspiration unmasks Brugada syndrome.  Heart 2011; 97: 167.    &nbsp; </font></p>          ]]></body>
<body><![CDATA[<!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b46"></a> <a href="#.46">46</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Govindan M, Batchvarov VN, Raju H, Shanmugam N, Bizrah M, Bastiaenen  R, et al.</b> Utility of high and standard right precordial leads during ajmaline  testing for the diagnosis of Brugada syndrome. Heart 2010; 96: 1904-8.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b47"></a> <a href="#.47">47</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Shimizu W.</b> Acquired forms of the Brugada syndrome. J Electrocardiol  2005; 38: 22-5.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"> <a name="48"></a><a href="#.48">48</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Strimel WJ, Woodruff A, Cheung P, Kirmani BF, Stephen Huang SK. </b>Brugada-like  electrocardiographic pattern induced by lamotrigine toxicity. Clin Neuropharmacol  2010; 33: 265-7.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b49"></a> <a href="#.49">49</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Nguyen T, Smythe J, Baranchuk A.</b> Rhabdomyoma of the interventricular  septum presenting as a Brugada phenocopy. Cardiol Young 2011; 4: 1-4.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="50"></a> <a href="#.50">50</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Riera AR, Uchida AH, Schapachnik E, Dubner S, Filho CF, Ferreira C.  </b>Propofol infusion syndrome and Brugada syndrome electrocardiographic phenocopy.  Cardiol J 2010; 17: 130-5.    &nbsp; </font></p>          ]]></body>
<body><![CDATA[<!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b51"></a> <a href="#.51">51</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Arce M, Riera AR, Femen&iacute;a F, Baranchuk A.</b> Brugada electrocardiographic  phenocopy in a patient with chronic Chagasic cardiomyopathy. Cardiol J  2010; 17: 525-7.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b52"></a> <a href="#.52">52</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Brugada R, Brugada J, Antzelevitch C, Kirsch GE, PotenzaD, Towbin JA,  et al.</b> Sodium channel blockers identify risk for sudden death in patients  with ST-segment elevation and right bundle branch block but structurally  normal hearts. Circulation 2000; 101: 510-5.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b53"></a> <a href="#.53">53</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado  D, et al. </b>Brugada syndrome: Report of the Second Consensus Conference:  Endorsed by the Heart Rhythm Society and the European Heart Rhythm Association.  Circulation 2005; 111: 659-70.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b54"></a> <a href="#.54">54</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Hong K, Brugada J, Oliva A, Berruezo-S&aacute;nchez A, Potenza D, Pollevick  GD, et al.</b> Value of electrocardiographic parameters and ajmaline test in  the diagnosis of Brugada syndrome caused by <i>SCN5A </i>mutations. Circulation  2004; 110: 3023-7.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b55"></a> <a href="#.54">55</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Meregalli PG, Ruijter JM, Hofman N, Bezzina CR, Wilde AA, Tan HL.</b> Diagnostic  value of flecainide testing in unmasking <i>SCN5A</i>-related Brugada syndrome.  J Cardiovasc Electrophysiol 2006; 17: 857-64.    &nbsp; </font></p>          ]]></body>
<body><![CDATA[<!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b56"></a> <a href="#.56">56</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Wolpert C, Echternach C, Veltmann C, Antzelevitch C, Thomas GP, Spehl  S, et al.</b> Intravenous drug challenge using flecainide and ajmaline in patients  with Brugada syndrome. Heart Rhythm 2005; 2: 254-60.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b57"></a> <a href="#.57">57</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Pitzalis MV, Anaclerio M, Iacoviello M, Forleo C, Guida P, Troccoli  R, et al.</b> QT-interval prolongation in right precordial leads: an additional  electrocardiographic hallmark of Brugada syndrome. J Am Coll Cardiol 2003;  42: 1632-7.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b58"></a> <a href="#.58">58</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Castro Hevia J, Antzelevitch C, Torn&eacute;s B&aacute;rzaga F, Dorantes S&aacute;nchez M,  Dorticos Balea F, Zayas Molina R, et al.</b> Tpeak-Tend and Tpeak-Tend dispersion  as risk factors for ventricular tachycardia/ventricular fibrillation in  patients with the Brugada syndrome. J Am Coll Cardiol 2006; 47: 1828-34.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b59"></a> <a href="#.59">59</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Antzelevitch C, Pollevick GD, Cordeiro JM, Casis O, Sanquinetti MC,  Aizawa Y, et al.</b> Loss-of-function mutations in the card&iacute;ac calcium channel  underlie a new clinical entity characterized by ST-segment elevation, short  QT intervals, and sudden cardiac death. Circulation 2007; 115: 442-9.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b60"></a> <a href="#.60">60</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Haarmark C, Graff C, Andersen MP, Hardahl T, Struijk JJ, Toft E, et  al.</b> Reference values of electrocardiogram repolarization variables in a  healthy population. J Electrocardiol 2010; 43: 31-9.    &nbsp; </font></p>       <multicol gutter="18" cols="2"></multicol>     ]]></body>
<body><![CDATA[<!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b61"></a> <a href="#.61">61</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Gupta P, Patel C, Patel H, Narayanaswamy S, Malhotra B, Green JT, et  al.</b> T(p-e)/QT ratio as an index of arrhythmogenesis. J Electrocardiol 2008;  41: 567-74.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b62"></a> <a href="#.62">62</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Letsas KP, Weber R, Astheimer K, Kalusche D, Arentz T.</b> Tpeak-Tend interval  and Tpeak-Tend/QT ratio as markers of ventricular tachycardia inducibility  in subjects with Brugada ECG phenotype. Europace 2010; 12: 271-4.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="63"></a> 63.&nbsp;&nbsp;&nbsp;&nbsp;<b>Amin AS, Boink GJ, Atrafi F, Spanjaar AM, Asghari-Roodsari A, Molenaar  RJ, et al.</b> Source Facilitatory and inhibitory effects of SCN5A mutations  on atrial fibrillation in Brugada syndrome. Europace 2011; 13: 968-75.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="64"></a> 64.&nbsp;&nbsp;&nbsp;&nbsp;<b>Kofune M, Watanabe I, Ohkubo K, Ashino S, Okumura Y, Nagashima K, et  al.</b> Abnormal atrial repolarization and depolarization contribute to the  inducibility of atrial fibrillation in Brugada syndrome. Int Heart J 2010;  51:159-65.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b65"></a> <a href="#.65">65</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Kakishita M, Kurita T, Matsuo K, Taguchi A, Suyama K, Shimizu W, et  al.</b> Mode of onset of ventricular fibrillation in patients with Brugada  syndrome detected by implantable cardioverter defibrillator therapy. J  Am Coll Cardiol 2000; 36:1646-55.    &nbsp; </font></p>          ]]></body>
<body><![CDATA[<!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="66"></a> <a href="#.66">66</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Gang ES, Priori SS, Chen PS.</b> Short coupled premature ventricular contraction  initiating ventricular fibrillation in a patient with Brugada syndrome.  J Cardiovasc Electrophysiol 2004; 15: 837.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="67"></a> <a href="#.67">67</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Chinushi M, Furushima H, Hosaka Y, Izumi D, Aizawa Y. </b>Ventricular fibrillation  and ventricular tachycardia triggered by late-coupled ventricular extrasystoles  in a Brugada syndrome patient. Pacing Clin Electrophysiol 2011; 34: e1-5.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="68"></a> <a href="#.68">68</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Leenhardt A, Glaser E, Burguera M.</b> Short-coupled variant of torsade  de pointes. A new electrocardiographic entity in the spectrum of idiopathic  ventricular tachyarrhythmias. Circulation 1994; 89: 206-15.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="69"></a> <a href="#.69">69</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Van den Branden B, Wever E, Boersma L.</b> Torsade de pointes with short  coupling interval. Acta Cardiol 2010; 65: 345-6.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b70"></a> <a href="#.70">70</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Allocca G, Proclemer A, Nucifora G.</b> Monomorphic ventricular tachycardia  in Brugada syndrome: clinical case and literature review. J Cardiovasc  Med (Hagerstown) 2008; 9: 842-6.    &nbsp; </font></p>          ]]></body>
<body><![CDATA[<!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="71"></a> <a href="#.71">71</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Sastry BK, Narasimhan C, Soma Raju B. </b>Brugada syndrome with monomorphic  ventricular tachycardia in a one-year-old child. Indian Heart J 2001; 53:  203-5.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="72"></a> <a href="#.72">72</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Frigo G, Rampazzo A, Bauce B.</b> Homozygous SCN5A mutation in Brugada syndrome  with monomorphic ventricular tachycardia and structural heart abnormalities.  Europace 2007; 9: 391-7.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="73"></a> <a href="#.73">73</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Bertomeu-Gonz&aacute;lez V, Ruiz-Granell R, Garc&iacute;a-Civera R, Morell-Cabedo  S, Ferrero A.</b> Syncopal monomorphic ventricular tachycardia with pleomorphism,  sensitive to antitachycardia pacing in a patient with Brugada syndrome.  Europace 2006; 8: 1048-50.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="74"></a> <a href="#.74">74</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Probst V, Evain S, Gournay V, Marie A, Schott JJ, Boisseau P, et al.</b>  Monomorphic ventricular tachycardia due to Brugada syndrome successfully  treated by hydroquinidine therapy in a 3-year-old child. J Cardiovasc Electrophysiol  2006; 17: 97-100.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="75"></a> <a href="#.75">75</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Dinckal MH, Davutoglu V, Akdemir I.</b> Incessant monomorphic ventricular  tachycardia during febrile illness in a patient with Brugada syndrome:  fatal electrical storm. Europace 2003; 5: 257-61.    &nbsp; </font></p>          ]]></body>
<body><![CDATA[<!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="76"></a> <a href="#.76">76</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Karaca M, Dinckal MH. </b>Monomorphic and propafenone-induced polymorphic  ventricular tachycardia in Brugada syndrome: a case report. Acta Cardiol  2006; 61: 481-4.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b77"></a> <a href="#.77">77</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Pinar Berm&uacute;dez E, Garc&iacute;a-Alberola A, Mart&iacute;nez S&aacute;nchez J, S&aacute;nchez Mu&ntilde;oz  JJ, Vald&eacute;s Ch&aacute;varri M.</b> Spontaneous sustained monomorphic ventricular tachycardia  after administration of ajmaline in a patient with Brugada syndrome. Pacing  Clin Electrophysiol 2000; 23: 407-9.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b78"></a> <a href="#.78">78</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>McIntyre WF, Femen&iacute;a F, Arce M, Trucco E, Palazzolo J, P&eacute;rez-Riera AR, et al.</b> Repetitive monomorphic ventricular tachycardia triggered by fever  in a patient with Brugada syndrome. </font><font color="#1f1a17" face="Century Schoolbook" size="1">  <font color="#2a2a2a" face="Verdana" size="2">Cardiol J 2011 (in press)</font><font color="#1f1a17" face="Verdana" size="2">.    &nbsp;</font></font><font color="#1f1a17" face="Verdana" size="2"> </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b79"></a> <a href="#.79">79</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Nishii N, Ogawa M, Morita H.</b> SCN5A mutation is associated with early  and frequent recurrence of ventricular fibrillation in patients with Brugada  syndrome. Circ J 2010; 74: 2572-8.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b80"></a> <a href="#.80">80</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Femen&iacute;a F, P&eacute;rez Riera AR.</b> Estratificaci&oacute;n del riesgo en las canalopat&iacute;as  cong&eacute;nitas. Revista Iberoamericana de Arritmolog&iacute;a [serie en Internet].2011  Feb; 1(2):[19p].Discponible en: <a href="http://www.ria-online.com/webapp/uploads/119_layouted_francisco_id-119_20110223.pdf">http://www.ria-online.com/webapp/uploads/119_layouted_francisco_id-119_20110223.pdf</a>.  Consultado (2/9/2011).    &nbsp; </font></p>          ]]></body>
<body><![CDATA[<p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b81"></a> <a href="#.81">81</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Viskin S. </b>Idiopathic ventricular fibrillation &ldquo;Le Syndrome d&rsquo;Ha&iuml;ssaguerre&rdquo;  and the fear of J waves. J Am Coll Cardiol 2009; 53: 620-2.&nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b82"></a> <a href="#.82">82</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Sarkozy A, Chierchia GB, Paparella G, Boussy T, De Asmundis C, Roos  M, et al.</b> Inferior and lateral electrocardiographic repolarization abnormalities  in Brugada syndrome. Circ Arrhythmia Electrophysiol 2009; 2: 154-61.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"> 83.&nbsp;&nbsp;&nbsp;&nbsp;<b>Riera AR, Ferreira C, Schapachnik E, Sanches PC, Moffa PJ.</b> Brugada syndrome  with atypical ECG: downsloping ST-segment elevation in inferior leads.  J Electrocardiol 2004; 37: 101-4.    &nbsp; </font></p>          <p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b84"></a> <a href="#.84">84</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Gussak I, Bjerregaard P, Kostis J. </b>Electrocardiographic &ldquo;lambda&rdquo; wave  and primary idiopathic cardiac asystole: a new clinical syndrome? J Electrocardiol  2004; 37: 105-7.&nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b85"></a> <a href="#.85">85</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Kukla P, Jastrzebski M, Sacha J, Bryniarski L.</b> Lambda-like ST segment  elevation in acute myocardial infarction: a new risk marker for ventricular  fibrillation? Three case reports. Kardiol Pol 2008; 66: 873-7.    &nbsp; </font></p>       <multicol gutter="18" cols="2"></multicol>     <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b86"></a> <a href="#.86">86</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Junttila MJ, Sager SJ, Freiser M, McGonagle S, Castellanos A, Myerburg  RJ.</b> Inferolateral early repolarization in athletes. J Interv Card Electrophysiol  2011; 31: 33-8.    &nbsp; </font></p>          ]]></body>
<body><![CDATA[<!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b87"></a><a href="#.87"> 87</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Ezaki K, Nakagawa M, Taniguchi Y.</b> Gender differences in the ST segment:  effect of androgen-deprivation therapy and possible role of testosterone.  Circ J 2010; 74: 2448-54.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b88"></a><a href="#.88"> 88</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Rosso R, Adler A, Halkin A.</b> Risk of sudden death among young individuals  with J waves and early repolarization: Putting the evidence into perspective.  Heart Rhythm 2011; 8: 923-9.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b89"></a> <a href="#.89">89</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Haruta D, Matsuo K, Tsuneto A. </b>Incidence and Prognostic Value of Early  Repolarization Pattern in the 12-Lead Electrocardiogram. Circulation 2011  (In Press).    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b90"></a> <a href="#.90">90</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Tikkanen JT, Junttila MJ, Anttonen O, Aro AL, Luttine S, Kerola T, et  al.</b> Early repolarization: electrocardiographic phenotypes associated with  favorable long-term outcome. Circulation 2011; 123: 2666-73.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b91"></a> <a href="#.91">91</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Noseworthy PA, Tikkanen JT, Porthan K, Oikarinen L, Pietila A, Harald  K, et al.</b> The early repolarization pattern in the general population clinical  correlates and heritability. J Am Coll Cardiol 2011; 57: 2284-9.    &nbsp;</font></p>     ]]></body>
<body><![CDATA[<!-- ref --><p align="left">    <font color="#1f1a17" face="Verdana" size="2"><a name="92"></a> <a href="#.92">92</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Napolitano C, Antzelevitch C.</b> Phenotypical manifestations of mutations  in the genes encoding subunits of the card&iacute;ac voltage-dependent L-type  calcium channel. Circ Res 2011; 108: 607-18.    &nbsp;     </font></p>      <ol>       </ol>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b93"></a> <a href="#.93">93</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Reinhard W, Kaess BM, Debiec R, Nelson CP, Stark K, Tobin MD, et al.</b>  Heritability of early repolarization: a population-based study. Circ Cardiovasc  Genet 2011; 4: 134-8.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b94"></a><a href="#.94"> 94</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Atarashi H, Ogawa S, Idiopathic Ventricular Fibrillation Investigators</b>.  New ECG criteria for high-risk Brugada syndrome. Circ J 2003; 67: 8-10.    &nbsp; </font></p>          <!-- ref --><p align="left"><font color="#1f1a17" face="Verdana" size="2"><a name="b95"></a> <a href="#.95">95</a>.&nbsp;&nbsp;&nbsp;&nbsp;<b>Makimoto H, Nakagawa E, Takaki H, Yamada Y, Okamura H, Noda T, et al.</b>  Augmented ST-segment elevation during recovery from exercise predicts card&iacute;ac  events in patients with Brugada syndrome. J Am Coll Cardiol 2010; 56: 1576-84.    &nbsp; </font></p>       <font face="Verdana" size="2">       <img src="images/Graphic_050.JPG" border="0" height="29" hspace="5" vspace="5" width="2"> </font>      ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Benito]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Brugada]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Brugada]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Brugada]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Brugada syndrome]]></article-title>
<source><![CDATA[Prog Cardiovasc Dis]]></source>
<year>2008</year>
<volume>51</volume>
<page-range>1-22</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Juang]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Brugada syndrome: an under recognized electrical disease in patients with sudden cardíac death]]></article-title>
<source><![CDATA[Cardiology]]></source>
<year>2004</year>
<volume>101</volume>
<page-range>157-69</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Benito]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Sarkozy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mont]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Henkens]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Berruezo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tamborero]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Gender differences in clinical manifestations of Brugada syndrome]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2008</year>
<volume>52</volume>
<page-range>1567-73</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oreto]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Corrado]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Delise]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Fedele]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gaita]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gentile]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Doubts of the cardiologist regarding an electrocardiogram presenting QRS V1-V2 complexes with positive terminal wave and ST segment elevation: Consensus Conference promoted by the Italian Cardiology Society]]></article-title>
<source><![CDATA[G Ital Cardiol (Rome)]]></source>
<year>2010</year>
<volume>11</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>3S-22S</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smits]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Koopmann]]></surname>
<given-names><![CDATA[TT]]></given-names>
</name>
<name>
<surname><![CDATA[Wilders]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Veldkamp]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Opthof]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Bhuiyan]]></surname>
<given-names><![CDATA[ZA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A mutation in the human cardíac sodium channel (E161K) contributes to sick sinus syndrome, conduction disease and Brugada syndrome in two families]]></article-title>
<source><![CDATA[J Mol Cell Cardiol]]></source>
<year>2005</year>
<volume>38</volume>
<page-range>969-81</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sumiyoshi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nakazato]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Tokano]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Yasuda]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mineda]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Nakata]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Sinus node dysfunction concomitant with Brugada syndrome]]></article-title>
<source><![CDATA[Circ J]]></source>
<year>2005</year>
<volume>69</volume>
<page-range>946-50</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fazelifar]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Haghjoo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Emkanjoo]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Alizadeh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Alasti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Peighambari]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Brugada-type ECG association with unexpected sick sinus syndrome]]></article-title>
<source><![CDATA[Pacing Clin Electrophysiol]]></source>
<year>2006</year>
<volume>29</volume>
<page-range>204-6</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilde]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Brugada]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Phenotypical manifestations of mutations in the genes encoding subunits of the cardiac sodium channel]]></article-title>
<source><![CDATA[Circ Res]]></source>
<year>2011</year>
<volume>108</volume>
<page-range>884-97</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bezzina]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Veldkamp]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[van Den Berg]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Postma]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[Rook]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Viersma]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A single Na(+) channel mutation causing both long-QT and Brugada syndromes]]></article-title>
<source><![CDATA[Circ Res]]></source>
<year></year>
<volume>85</volume>
<page-range>1206-13</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Neu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Eiselt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Paul]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sauter]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Stallmeyer]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Isbrandt]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A homozygous SCN5A mutation in a severe, recessive type of cardíac conduction disease]]></article-title>
<source><![CDATA[Hum Mutat]]></source>
<year>2010</year>
<page-range>1609-21</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hayashi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Sumiyoshi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yasuda]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Komatsu]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sekita]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kawano]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prevalence of the Brugada-type electrocardiogram and incidence of Brugada syndrome in patients with sick sinus syndrome]]></article-title>
<source><![CDATA[Circ J]]></source>
<year>2010</year>
<volume>74</volume>
<page-range>271-7</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Letsas]]></surname>
<given-names><![CDATA[KP]]></given-names>
</name>
<name>
<surname><![CDATA[Weber]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Astheimer]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Mihas]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Stockinger]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Blum]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Predictors of atrial tachyarrhythmias in subjects with type 1 ECG pattern of Brugada syndrome]]></article-title>
<source><![CDATA[Pacing Clin Electrophysiol]]></source>
<year>2009</year>
<volume>32</volume>
<page-range>500-5</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Furukawa]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yamada]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Okuyama]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Morita]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Iwasaki]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Increased Intraatrial Conduction Abnormality Assessed by P-Wave Signal-Averaged Electrocardiogram in Patients with Brugada Syndrome]]></article-title>
<source><![CDATA[Pacing Clin Electrophysiol]]></source>
<year>2011</year>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meregalli]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Ruijter]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Hofman]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Bezzina]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Wilde]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Diagnostic value of flecainide testing in unmasking SCN5A-related Brugada syndrome]]></article-title>
<source><![CDATA[J Cardiovasc Electrophysiol]]></source>
<year>2006</year>
<volume>17</volume>
<page-range>857-64</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smits]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Eckardt]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Probst]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Bezzina]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Schott]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Temme]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Genotype-phenotype relationship in Brugada syndrome: electrocardiographic features differentiate SCN5A-related patients from non-SCN5A-related patients]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2002</year>
<volume>40</volume>
<page-range>350-6</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miyamoto]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hayashi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Makiyama]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshino]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Mizusawa]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Sugimoto]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Risk determinants in individuals with a spontaneous type 1 Brugada ECG]]></article-title>
<source><![CDATA[Circ J]]></source>
<year>2011</year>
<volume>75</volume>
<page-range>844-51</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pastore]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Moffa]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Spiritus]]></surname>
<given-names><![CDATA[MO]]></given-names>
</name>
<name>
<surname><![CDATA[Tobias]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[de Moraes]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Del Nero Junior]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Fascicular blocks of the right branch: Standardization of vectorelectrocardiographic findings]]></article-title>
<source><![CDATA[Arq Bras Cardiol]]></source>
<year>1983</year>
<volume>41</volume>
<page-range>161-6</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez Riera]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Schapachnik]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Value of 12 leads electrocardiogram and derived methodologies in the diagnosis of Brugada disease]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Antzelevitch]]></surname>
<given-names><![CDATA[Ch]]></given-names>
</name>
<name>
<surname><![CDATA[Brugada]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Brugada]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Brugada]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[The Brugada Syndrome From Bench to Bedside]]></source>
<year>2005</year>
<page-range>87-110</page-range><publisher-loc><![CDATA[Oxford ]]></publisher-loc>
<publisher-name><![CDATA[Blackwell Science]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coronel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Casini]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Koopmann]]></surname>
<given-names><![CDATA[TT]]></given-names>
</name>
<name>
<surname><![CDATA[Wilms-Schopman]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Verkerk]]></surname>
<given-names><![CDATA[AO]]></given-names>
</name>
<name>
<surname><![CDATA[de Groot]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Right ventricular fibrosis and conduction delay in a patient with clinical signs of Brugada syndrome: a combined elctrophysiological, genetic, histopathologic, and computational study]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2005</year>
<volume>112</volume>
<page-range>2769-77</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Junttila]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Brugada]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Lizotte]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[De Zutter]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sarkozy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Differences in 12-lead electrocardiogram between symptomatic and asymptomatic Brugada syndrome patients]]></article-title>
<source><![CDATA[J Cardiovasc Electrophysiol]]></source>
<year>2007</year>
<volume>19</volume>
<page-range>380-3</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ohkubo]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Watanabe]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Okumura]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ashino]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kofine]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nagashima]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prolonged QRS duration in lead V2 and risk of life-threatening ventricular Arrhythmia in patients with Brugada syndrome]]></article-title>
<source><![CDATA[Int Heart J]]></source>
<year>2011</year>
<volume>52</volume>
<page-range>98-102</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Takagi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yokoyama]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Aonuma]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Aihara]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Hiraoka]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Clinical characteristics and risk stratification in symptomatic and asymptomatic patients with Brugada syndrome: multicenter study in Japan]]></article-title>
<source><![CDATA[J Cardiovasc Electrophysiol]]></source>
<year>2007</year>
<volume>18</volume>
<page-range>1244-51</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gussak]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Antzelevitch]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bjerregaard]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Towbin]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Chaitman]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The Brugada syndrome: clinical, electrophysiologic and genetic aspects]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>1999</year>
<volume>33</volume>
<page-range>5-15</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rolf]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Haverkamp]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Eckardt]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[True Right Bundle Branch Block Masking the Typical ECG in Brugada Syndrome]]></article-title>
<source><![CDATA[Pacing Clin Electrophysiol]]></source>
<year>2005</year>
<volume>28</volume>
<page-range>258-9</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez Riera]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hopman]]></surname>
<given-names><![CDATA[WM]]></given-names>
</name>
<name>
<surname><![CDATA[McIntyre]]></surname>
<given-names><![CDATA[WF]]></given-names>
</name>
<name>
<surname><![CDATA[Baranchuk]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Electrovectorcardiographic characterization of the type-1 Brugada ECG pattern]]></article-title>
<source><![CDATA[Europace]]></source>
<year>2011</year>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Das]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Jacob]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mahenthiran]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Significance of a fragmented QRS complex versus a Q wave in patients with coronary artery disease]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2006</year>
<volume>113</volume>
<page-range>2495-501</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Das]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Maskoun]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Michael]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Suradi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Desai]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Fragmented QRS on twelve-lead electrocardiogram predicts arrhythmic events in patients with ischemic and nonischemic cardiomyopathy]]></article-title>
<source><![CDATA[Heart Rhythm]]></source>
<year>2010</year>
<volume>7</volume>
<page-range>74-80</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saumarez]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Chojnowska]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Derksen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pytkowski]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sterlinski]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Sudden death in noncoronary heart disease is associated with delayed paced ventricular activation]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2003</year>
<volume>107</volume>
<page-range>2595-600</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baranchuk]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Femenía]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[López Diez]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Muratore]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Valentino]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Retyk]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Fragmented ECG in Chagas&rsquo: Cardiomyopathy (FECHA Study)]]></article-title>
<source><![CDATA[Cardiol J. In Press]]></source>
<year>2011</year>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peters]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Trümmel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Koehler]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[QRS fragmentation in standard ECG as a diagnostic marker of arrhythmogenic right ventricular dysplasia-cardiomyopathy]]></article-title>
<source><![CDATA[Heart Rhythm]]></source>
<year>2008</year>
<volume>5</volume>
<page-range>1417-21</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morita]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kusano]]></surname>
<given-names><![CDATA[KF]]></given-names>
</name>
<name>
<surname><![CDATA[Miura]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Nagase]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Nakamura]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Morita]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Fragmented QRS as a marker of conduction abnormality and a predictor of prognosis of Brugada syndrome]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2008</year>
<volume>118</volume>
<page-range>1697-704</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morita]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Zipes]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Brugada syndrome: insights of ST elevation, arrhythmogenicity, and risk stratification from experimental observations]]></article-title>
<source><![CDATA[Heart Rhythm]]></source>
<year>2009</year>
<volume>6</volume>
<page-range>S34-43</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Babai Bigi]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Aslani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Shahrzad]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[aVR sign as a risk factor for life-threatening arrhythmic events in patients with Brugada syndrome]]></article-title>
<source><![CDATA[Heart Rhythm]]></source>
<year>2007</year>
<volume>4</volume>
<page-range>1009-12</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Riera]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira Filho]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Dubner]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Barbosa Barros]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Femenía]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Clinical value of lead aVR]]></article-title>
<source><![CDATA[Ann Noninvasive Electrocardiol]]></source>
<year>2011</year>
<volume>16</volume>
<page-range>295-302</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilde]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Antzelevitch]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Borggrefe]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Brugada]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Brugada]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Brugada]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Study Group on the Molecular Basis of Arrhythmias of the European Society of Cardiology Proposed diagnostic criteria for the Brugada syndrome: consensus report]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2002</year>
<volume>106</volume>
<page-range>2514-9</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Take]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Morita]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Nagase]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Morita]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Toh]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Spontaneous electrocardiogram alterations predict ventricular fibrillation in Brugada syndrome]]></article-title>
<source><![CDATA[Heart Rhythm.]]></source>
<year>2011</year>
</nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Farre]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The Brugada syndrome: Do we need more than the 12-lead ECG?]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2000</year>
<volume>21</volume>
<page-range>264-5</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sangwatanaroj]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Prechawat]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sunsaneewitayakul]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Sitthisook]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tosukhowong]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Tunsanga]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Right ventricular electrocardiographic leads for detection of Brugada syndrome in sudden unexplained death syndrome survivors and their relatives]]></article-title>
<source><![CDATA[Clin Cardiol]]></source>
<year>2001</year>
<volume>24</volume>
<page-range>776-81</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sangwatanaroj]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Prechawat]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sunsaneewitayakul]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Sitthisook]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tosukhowong]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Tunsanga]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[New electrocardiographic leads and the procainamide test for the detection of the Brugada sign in sudden unexplained death syndrome survivors and their relatives]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2001</year>
<volume>22</volume>
<page-range>2290-6</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nagatomo]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Abe]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Oginosawa]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Araki]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nakashima]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Reproduction of typical electrocardiographic findings of the Brugada syndrome using modified precordial leads]]></article-title>
<source><![CDATA[J UOEH]]></source>
<year>2002</year>
<volume>24</volume>
<page-range>383-9</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nagase]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kusano]]></surname>
<given-names><![CDATA[KF]]></given-names>
</name>
<name>
<surname><![CDATA[Morita]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Fujimoto]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Kakishita]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nakamura]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Epicardial electrogram of the right ventricular outflow tract in patients with the brugada syndrome: Using the epicardial lead]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2002</year>
<volume>39</volume>
<page-range>1992-5</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Takagi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Toda]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Takeuchi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshikawa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Utility of right precordial leads at higher intercostal space positions to diagnose Brugada syndrome]]></article-title>
<source><![CDATA[Pacing Clin Electrophysiol]]></source>
<year>2002</year>
<volume>25</volume>
<page-range>241-2</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cabezon Ruiz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Errazquin Saenz De Tejada]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Pedrote Martínez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Morán Risco]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Marín Morgado]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Normal Conventional Electrocardiogram with Negative Pharmacological Stress Test does Not Rule out Brugada Syndrome]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2003</year>
<volume>56</volume>
<page-range>107-10</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Butz]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Vogt]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Vielhauer]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Welzel]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Langer]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Horstkotte]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Detection of a type 1 Brugada ECG by ECG recording at a higher intercostal space of leads V(1) and V (2)]]></article-title>
<source><![CDATA[Herz]]></source>
<year>2010</year>
<volume>35</volume>
<page-range>112</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vatasescu]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Dan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dorobantu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Deep inspiration unmasks Brugada syndrome]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2011</year>
<volume>97</volume>
<page-range>167</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Govindan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Batchvarov]]></surname>
<given-names><![CDATA[VN]]></given-names>
</name>
<name>
<surname><![CDATA[Raju]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Shanmugam]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Bizrah]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bastiaenen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Utility of high and standard right precordial leads during ajmaline testing for the diagnosis of Brugada syndrome]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2010</year>
<volume>96</volume>
<page-range>1904-8</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shimizu]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Acquired forms of the Brugada syndrome]]></article-title>
<source><![CDATA[J Electrocardiol]]></source>
<year>2005</year>
<volume>38</volume>
<page-range>22-5</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Strimel]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Woodruff]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cheung]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Kirmani]]></surname>
<given-names><![CDATA[BF]]></given-names>
</name>
<name>
<surname><![CDATA[Stephen Huang]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Brugada-like electrocardiographic pattern induced by lamotrigine toxicity]]></article-title>
<source><![CDATA[Clin Neuropharmacol]]></source>
<year>2010</year>
<volume>33</volume>
<page-range>265-7</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Smythe]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Baranchuk]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Rhabdomyoma of the interventricular septum presenting as a Brugada phenocopy]]></article-title>
<source><![CDATA[Cardiol Young]]></source>
<year>2011</year>
<volume>4</volume>
<page-range>1-4</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Riera]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Uchida]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Schapachnik]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Dubner]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Filho]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Propofol infusion syndrome and Brugada syndrome electrocardiographic phenocopy]]></article-title>
<source><![CDATA[Cardiol J]]></source>
<year>2010</year>
<volume>17</volume>
<page-range>130-5</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arce]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Riera]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Femenía]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Baranchuk]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Brugada electrocardiographic phenocopy in a patient with chronic Chagasic cardiomyopathy]]></article-title>
<source><![CDATA[Cardiol J]]></source>
<year>2010</year>
<volume>17</volume>
<page-range>525-7</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brugada]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Brugada]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Antzelevitch]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kirsch]]></surname>
<given-names><![CDATA[GE]]></given-names>
</name>
<name>
<surname><![CDATA[Potenza]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Towbin]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2000</year>
<volume>101</volume>
<page-range>510-5</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Antzelevitch]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Brugada]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Borggrefe]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Brugada]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Brugada]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Corrado]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Brugada syndrome: Report of the Second Consensus Conference: Endorsed by the Heart Rhythm Society and the European Heart Rhythm Association]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2005</year>
<volume>111</volume>
<page-range>659-70</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Brugada]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Oliva]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Berruezo-Sánchez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Potenza]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Pollevick]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Value of electrocardiographic parameters and ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2004</year>
<volume>110</volume>
<page-range>3023-7</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meregalli]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Ruijter]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Hofman]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Bezzina]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Wilde]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Diagnostic value of flecainide testing in unmasking SCN5A-related Brugada syndrome]]></article-title>
<source><![CDATA[Cardiovasc Electrophysiol]]></source>
<year>2006</year>
<volume>17</volume>
<page-range>857-64</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wolpert]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Echternach]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Veltmann]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Antzelevitch]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
<name>
<surname><![CDATA[Spehl]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome]]></article-title>
<source><![CDATA[Heart Rhythm]]></source>
<year>2005</year>
<volume>2</volume>
<page-range>254-60</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pitzalis]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Anaclerio]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Iacoviello]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Forleo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Guida]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Troccoli]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[QT-interval prolongation in right precordial leads: an additional electrocardiographic hallmark of Brugada syndrome]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2003</year>
<volume>42</volume>
<page-range>1632-7</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castro Hevia]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Antzelevitch]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Tornés Bárzaga]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Dorantes Sánchez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dorticos Balea]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Zayas Molina]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2006</year>
<volume>47</volume>
<page-range>1828-34</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Antzelevitch]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Pollevick]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
<name>
<surname><![CDATA[Cordeiro]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Casis]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Sanquinetti]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Aizawa]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Loss-of-function mutations in the cardíac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2007</year>
<volume>115</volume>
<page-range>442-9</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haarmark]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Graff]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Andersen]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Hardahl]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Struijk]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Toft]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Reference values of electrocardiogram repolarization variables in a healthy population]]></article-title>
<source><![CDATA[J Electrocardiol]]></source>
<year>2010</year>
<volume>43</volume>
<page-range>31-9</page-range></nlm-citation>
</ref>
<ref id="B61">
<label>61</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Narayanaswamy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Malhotra]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[T(p-e)/QT ratio as an index of arrhythmogenesis]]></article-title>
<source><![CDATA[J Electrocardiol]]></source>
<year>2008</year>
<volume>41</volume>
<page-range>567-74</page-range></nlm-citation>
</ref>
<ref id="B62">
<label>62</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Letsas]]></surname>
<given-names><![CDATA[KP]]></given-names>
</name>
<name>
<surname><![CDATA[Weber]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Astheimer]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kalusche]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Arentz]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Tpeak-Tend interval and Tpeak-Tend/QT ratio as markers of ventricular tachycardia inducibility in subjects with Brugada ECG phenotype]]></article-title>
<source><![CDATA[Europace]]></source>
<year>2010</year>
<volume>12</volume>
<page-range>271-4</page-range></nlm-citation>
</ref>
<ref id="B63">
<label>63</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amin]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Boink]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Atrafi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Spanjaar]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Asghari-Roodsari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Molenaar]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Source Facilitatory and inhibitory effects of SCN5A mutations on atrial fibrillation in Brugada syndrome]]></article-title>
<source><![CDATA[Europace]]></source>
<year>2011</year>
<volume>13</volume>
<page-range>968-75</page-range></nlm-citation>
</ref>
<ref id="B64">
<label>64</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kofune]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Watanabe]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ohkubo]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ashino]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Okumura]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Nagashima]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Abnormal atrial repolarization and depolarization contribute to the inducibility of atrial fibrillation in Brugada syndrome]]></article-title>
<source><![CDATA[Int Heart J]]></source>
<year>2010</year>
<volume>51</volume>
<page-range>159-65</page-range></nlm-citation>
</ref>
<ref id="B65">
<label>65</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kakishita]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kurita]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Matsuo]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Taguchi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Suyama]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Shimizu]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Mode of onset of ventricular fibrillation in patients with Brugada syndrome detected by implantable cardioverter defibrillator therapy]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2000</year>
<volume>36</volume>
<page-range>1646-55</page-range></nlm-citation>
</ref>
<ref id="B66">
<label>66</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gang]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Priori]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Short coupled premature ventricular contraction initiating ventricular fibrillation in a patient with Brugada syndrome]]></article-title>
<source><![CDATA[J Cardiovasc Electrophysiol]]></source>
<year>2004</year>
<volume>15</volume>
<page-range>837</page-range></nlm-citation>
</ref>
<ref id="B67">
<label>67</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chinushi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Furushima]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hosaka]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Izumi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Aizawa]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Ventricular fibrillation and ventricular tachycardia triggered by late-coupled ventricular extrasystoles in a Brugada syndrome patient]]></article-title>
<source><![CDATA[Pacing Clin Electrophysiol]]></source>
<year>2011</year>
<volume>34</volume>
<page-range>e1-5</page-range></nlm-citation>
</ref>
<ref id="B68">
<label>68</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leenhardt]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Glaser]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Burguera]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Short-coupled variant of torsade de pointes: A new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1994</year>
<volume>89</volume>
<page-range>206-15</page-range></nlm-citation>
</ref>
<ref id="B69">
<label>69</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van den Branden]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Wever]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Boersma]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Torsade de pointes with short coupling interval]]></article-title>
<source><![CDATA[Acta Cardiol]]></source>
<year>2010</year>
<volume>65</volume>
<page-range>345-6</page-range></nlm-citation>
</ref>
<ref id="B70">
<label>70</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Allocca]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Proclemer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nucifora]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Monomorphic ventricular tachycardia in Brugada syndrome: clinical case and literature review]]></article-title>
<source><![CDATA[J Cardiovasc Med (Hagerstown)]]></source>
<year>2008</year>
<volume>9</volume>
<page-range>842-6</page-range></nlm-citation>
</ref>
<ref id="B71">
<label>71</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sastry]]></surname>
<given-names><![CDATA[BK]]></given-names>
</name>
<name>
<surname><![CDATA[Narasimhan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Soma Raju]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Brugada syndrome with monomorphic ventricular tachycardia in a one-year-old child]]></article-title>
<source><![CDATA[Indian Heart J]]></source>
<year>2001</year>
<volume>53</volume>
<page-range>203-5</page-range></nlm-citation>
</ref>
<ref id="B72">
<label>72</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Frigo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rampazzo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bauce]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Homozygous SCN5A mutation in Brugada syndrome with monomorphic ventricular tachycardia and structural heart abnormalities]]></article-title>
<source><![CDATA[Europace]]></source>
<year>2007</year>
<volume>9</volume>
<page-range>391-7</page-range></nlm-citation>
</ref>
<ref id="B73">
<label>73</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bertomeu-González]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz-Granell]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[García-Civera]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Morell-Cabedo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrero]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Syncopal monomorphic ventricular tachycardia with pleomorphism, sensitive to antitachycardia pacing in a patient with Brugada syndrome]]></article-title>
<source><![CDATA[Europace]]></source>
<year>2006</year>
<volume>8</volume>
<page-range>1048-50</page-range></nlm-citation>
</ref>
<ref id="B74">
<label>74</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Probst]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Evain]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gournay]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Marie]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schott]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Boisseau]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Monomorphic ventricular tachycardia due to Brugada syndrome successfully treated by hydroquinidine therapy in a 3-year-old child]]></article-title>
<source><![CDATA[J Cardiovasc Electrophysiol]]></source>
<year>2006</year>
<volume>17</volume>
<page-range>97-100</page-range></nlm-citation>
</ref>
<ref id="B75">
<label>75</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dinckal]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Davutoglu]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Akdemir]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Incessant monomorphic ventricular tachycardia during febrile illness in a patient with Brugada syndrome: fatal electrical storm]]></article-title>
<source><![CDATA[Europace]]></source>
<year>2003</year>
<volume>5</volume>
<page-range>257-61</page-range></nlm-citation>
</ref>
<ref id="B76">
<label>76</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Karaca]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dinckal]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Monomorphic and propafenone-induced polymorphic ventricular tachycardia in Brugada syndrome: a case report]]></article-title>
<source><![CDATA[Acta Cardiol]]></source>
<year>2006</year>
<volume>61</volume>
<page-range>481-4</page-range></nlm-citation>
</ref>
<ref id="B77">
<label>77</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pinar Bermúdez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[García-Alberola]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Sánchez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez Muñoz]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Valdés Chávarri]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Spontaneous sustained monomorphic ventricular tachycardia after administration of ajmaline in a patient with Brugada syndrome]]></article-title>
<source><![CDATA[Pacing Clin Electrophysiol]]></source>
<year>2000</year>
<volume>23</volume>
<page-range>407-9</page-range></nlm-citation>
</ref>
<ref id="B78">
<label>78</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McIntyre]]></surname>
<given-names><![CDATA[WF]]></given-names>
</name>
<name>
<surname><![CDATA[Femenía]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Arce]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Trucco]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Palazzolo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez-Riera]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Repetitive monomorphic ventricular tachycardia triggered by fever in a patient with Brugada syndrome]]></article-title>
<source><![CDATA[Cardiol J]]></source>
<year>2011</year>
</nlm-citation>
</ref>
<ref id="B79">
<label>79</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nishii]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ogawa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Morita]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[SCN5A mutation is associated with early and frequent recurrence of ventricular fibrillation in patients with Brugada syndrome]]></article-title>
<source><![CDATA[Circ J]]></source>
<year>2010</year>
<volume>74</volume>
<page-range>2572-8</page-range></nlm-citation>
</ref>
<ref id="B80">
<label>80</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Femenía]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Riera]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Estratificación del riesgo en las canalopatías congénitas]]></article-title>
<source><![CDATA[Revista Iberoamericana de Arritmología]]></source>
<year>.201</year>
<month>1 </month>
<day>Fe</day>
<volume>1</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>19</page-range></nlm-citation>
</ref>
<ref id="B81">
<label>81</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Viskin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Idiopathic ventricular fibrillation Le Syndrome d´Haïssaguerre and the fear of J waves]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2009</year>
<volume>53</volume>
<page-range>620-2</page-range></nlm-citation>
</ref>
<ref id="B82">
<label>82</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sarkozy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chierchia]]></surname>
<given-names><![CDATA[GB]]></given-names>
</name>
<name>
<surname><![CDATA[Paparella]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Boussy]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[De Asmundis]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Roos]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Inferior and lateral electrocardiographic repolarization abnormalities in Brugada syndrome]]></article-title>
<source><![CDATA[Circ Arrhythmia Electrophysiol]]></source>
<year>2009</year>
<volume>2</volume>
<page-range>154-61</page-range></nlm-citation>
</ref>
<ref id="B83">
<label>83</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Riera]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Schapachnik]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Sanches]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Moffa]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Brugada syndrome with atypical ECG: downsloping ST-segment elevation in inferior leads]]></article-title>
<source><![CDATA[J Electrocardiol]]></source>
<year>2004</year>
<volume>37</volume>
<page-range>101-4</page-range></nlm-citation>
</ref>
<ref id="B84">
<label>84</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gussak]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Bjerregaard]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Kostis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Electrocardiographic 'lambda' wave and primary idiopathic cardiac asystole: a new clinical syndrome?]]></article-title>
<source><![CDATA[J Electrocardiol]]></source>
<year>2004</year>
<volume>37</volume>
<page-range>105-7</page-range></nlm-citation>
</ref>
<ref id="B85">
<label>85</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kukla]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Jastrzebski]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sacha]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bryniarski]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Lambda-like ST segment elevation in acute myocardial infarction: a new risk marker for ventricular fibrillation? Three case reports]]></article-title>
<source><![CDATA[Kardiol Pol]]></source>
<year>2008</year>
<volume>66</volume>
<page-range>873-7</page-range></nlm-citation>
</ref>
<ref id="B86">
<label>86</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Junttila]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sager]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Freiser]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[McGonagle]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Castellanos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Myerburg]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Inferolateral early repolarization in athletes]]></article-title>
<source><![CDATA[J Interv Card Electrophysiol]]></source>
<year>2011</year>
<volume>31</volume>
<page-range>33-8</page-range></nlm-citation>
</ref>
<ref id="B87">
<label>87</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ezaki]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Nakagawa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Taniguchi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Gender differences in the ST segment: effect of androgen-deprivation therapy and possible role of testosterone]]></article-title>
<source><![CDATA[Circ J]]></source>
<year>2010</year>
<volume>74</volume>
<page-range>2448-54</page-range></nlm-citation>
</ref>
<ref id="B88">
<label>88</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosso]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Adler]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Halkin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Risk of sudden death among young individuals with J waves and early repolarization: Putting the evidence into perspective]]></article-title>
<source><![CDATA[Heart Rhythm]]></source>
<year>2011</year>
<volume>8</volume>
<page-range>923-9</page-range></nlm-citation>
</ref>
<ref id="B89">
<label>89</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haruta]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Matsuo]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Tsuneto]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Incidence and Prognostic Value of Early Repolarization Pattern in the 12-Lead Electrocardiogram]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2011</year>
</nlm-citation>
</ref>
<ref id="B90">
<label>90</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tikkanen]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Junttila]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Anttonen]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Aro]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Luttine]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kerola]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Early repolarization: electrocardiographic phenotypes associated with favorable long-term outcome]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2011</year>
<volume>123</volume>
<page-range>2666-73</page-range></nlm-citation>
</ref>
<ref id="B91">
<label>91</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Noseworthy]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Tikkanen]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Porthan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Oikarinen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pietila]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Harald]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The early repolarization pattern in the general population clinical correlates and heritability]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2011</year>
<volume>57</volume>
<page-range>2284-9</page-range></nlm-citation>
</ref>
<ref id="B92">
<label>92</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Napolitano]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Antzelevitch]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Phenotypical manifestations of mutations in the genes encoding subunits of the cardíac voltage-dependent L-type calcium channel]]></article-title>
<source><![CDATA[Circ Res]]></source>
<year>2011</year>
<volume>108</volume>
<page-range>607-18</page-range></nlm-citation>
</ref>
<ref id="B93">
<label>93</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reinhard]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Kaess]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[Debiec]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Nelson]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Stark]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Tobin]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Heritability of early repolarization: a population-based study]]></article-title>
<source><![CDATA[Circ Cardiovasc Genet]]></source>
<year>2011</year>
<volume>4</volume>
<page-range>134-8</page-range></nlm-citation>
</ref>
<ref id="B94">
<label>94</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Atarashi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ogawa]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Idiopathic Ventricular Fibrillation Investigators: New ECG criteria for high-risk Brugada syndrome]]></article-title>
<source><![CDATA[Circ J]]></source>
<year>2003</year>
<volume>67</volume>
<page-range>8-10</page-range></nlm-citation>
</ref>
<ref id="B95">
<label>95</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Makimoto]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Nakagawa]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Takaki]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Yamada]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Okamura]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Noda]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Augmented ST-segment elevation during recovery from exercise predicts cardíac events in patients with Brugada syndrome]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2010</year>
<volume>56</volume>
<page-range>1576-84</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
